

**From:** Hallett, Mark (NIH/NINDS) [E]  
**To:** Koroshetz, Walter (NIH/NINDS) [E]; NINDS Press Team  
**Subject:** RE: reporter seeks interview for article in NY Times Magazine  
**Date:** Thursday, August 16, 2018 7:17:22 PM

Thanks, Walter. Two points. [REDACTED] (b) (5), (b) (6)

[REDACTED] Second, Dan says he wants only to talk with me about functional neurological disorders in general and not about Cuba (although the article will be about Cuba). IN any event, I will do what I am told.....mark

Mark Hallett, M.D., D.M.(hon)  
 Chief, Human Motor Control Section, NINDS  
 NIH, Building 10, Room 7D37  
 10 Center Dr MSC 1428  
 Bethesda, MD 20892-1428  
 Tel: 301-496-9526  
 Fax: 301-480-2286  
 email: hallettm@ninds.nih.gov  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** Koroshetz, Walter (NIH/NINDS) [E]  
**Sent:** Thursday, August 16, 2018 6:32 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>; NINDS Press Team <NINDSPressTeam@ninds.nih.gov>  
**Subject:** RE: reporter seeks interview for article in NY Times Magazine

[REDACTED] (b) (5), (b) (6)

walter

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Monday, August 13, 2018 8:48 PM  
**To:** NINDS Press Team <NINDSPressTeam@ninds.nih.gov>  
**Cc:** Koroshetz, Walter (NIH/NINDS) [E] <koroshetzw@ninds.nih.gov>  
**Subject:** FW: reporter seeks interview for article in NY Times Magazine

Dear Press Team,

As you see below, Dan Hurley will be writing you asking for permission to talk with me about functional neurological disorders in an article that he is planning about the Cuban diplomats. I tried to turn him down, but he is persistent. You can decide whether it is appropriate. If I do talk with him, I would stay strictly away from Cuba and talk only about the disorder in general. However, even this might be considered inappropriate at this point in time. [REDACTED] (b) (5), (b) (6)

[REDACTED]  
 [REDACTED] In any event, this is a very

sensitive issue, again as you likely know, so any interview should be approved by HHS at highest level. I will copy Walter Koroshetz to keep him in the loop too.....mark

**From:** Dan Hurley [mailto:[hurleydan1@gmail.com](mailto:hurleydan1@gmail.com)]  
**Sent:** Monday, August 13, 2018 8:26 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** Re: reporter seeks interview for article in NY Times Magazine

Hi Mark: Thanks for your reply last week. I was away in Vermont. I appreciate your concern that the NIH press office might not want you to discuss this topic. As a leading scientist who has published dozens of articles on functional neurological disorders, you are in an excellent position to discuss the general topic. Your position as chief of the Human Motor Control Section at NINDS lends your views particular weight. In over 25 years as a medical reporter specializing in neurology, I can't recall a single time that the NIH press office refused a request for an interview with a scientist on his or her area of specialty. I am happy to respect any conditions or concerns you or the press office might have. I'm certainly not trying to get you in trouble. Almost every article I write ends up quoting docs with different points of view. That's how both science and journalism work. So.... would you mind if I reach out to the NINDS press office, to ask their permission to speak with you? Thanks, Dan

On Mon, Aug 6, 2018 at 6:35 PM, Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)> wrote:

Hi Dan,  
 The NIH is concerned about us in HHS getting involved with matters of the State Department. While I originally helped Jon Stone with the letter to JAMA, the NIH did not want me to sign on, so I do not know what its final form was. I agree that I have not heard that it was published. So I suspect that it is unlikely that NIH (HHS) will allow an interview of me on this topic as the article is focused on the Cuban problem. I apologize that I cannot help you. I am sure, however, that you can find many other experts in the USA who could provide you the information and points of view that you are seeking.  
 Mark

Mark Hallett, M.D., D.M.(hon)  
 Chief, Human Motor Control Section, NINDS  
 NIH, Building 10, Room 7D37  
 10 Center Dr MSC 1428  
 Bethesda, MD 20892-1428  
 Tel: 301-496-9526  
 Fax: 301-480-2286  
 email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** Dan Hurley [mailto:[hurleydan1@gmail.com](mailto:hurleydan1@gmail.com)]  
**Sent:** Monday, August 06, 2018 6:16 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** reporter seeks interview for article in NY Times Magazine

Hi Dr. Hallett: I'm a science reporter specializing in neurology topics, and wrote an article in

February for Neurology Today about the US diplomats in Cuba who have experienced a variety of symptoms, including dizziness, after hearing unusual sounds. I interviewed Jon Stone for that article, who mentioned that you had coauthored with him and others a letter submitted to JAMA making the case that the symptoms were likely functional, rather than due to a "sonic attack." (I don't believe that JAMA ever published the letter?)

I am now writing a longer article for the New York Times Magazine about this ongoing question of what has caused the diplomats' symptoms, and the broader subject of just how powerful (and misunderstood) functional disorders can be. I've looked over some of your fascinating studies on functional movement disorders.

I would very much like to interview you about this subject. Is there a good time when we might talk by telephone in the next week or two? Thanks very much, Dan Hurley

**From:** Hallett, Mark (NIH/NINDS) [E]  
**To:** (b) (4)  
**Subject:** RE: A short media request from (b) (4)  
**Date:** Tuesday, March 13, 2018 11:44:26 AM

---

NIH will not allow this. Sorry.

Mark Hallett, M.D., D.M.(hon)  
Chief, Human Motor Control Section, NINDS  
NIH, Building 10, Room 7D37  
10 Center Dr MSC 1428  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** (b) (4)  
**Sent:** Tuesday, March 13, 2018 11:41 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** A short media request from (b) (4)

Dear Dr. Hallett,

I hope this email finds you well. My name is (b) (4) and I'm the executive producer for (b) (4). I am writing to invite you to be part of our show.

We are currently producing a report on the alleged sonic attack against American diplomats in Havana, Cuba. And we are interested in getting a medical perspective from you on the subject. We are particularly interested in discussing our brain's susceptibility to mass hysteria or high stress.

Ideally, we would like to schedule the interview sometime this week as soon as possible. Might you have any availability? (b) (4) We could also bring a camera to your offices if that is more convenient.

This interview would be a short, on-camera comment, which will be featured as a key expert opinion in a larger produced piece. The whole process, including set-up, should not take more than 20 minutes.

I am happy to answer any questions you may have about our show or the angle of the story. I can be reached anytime at (b) (4) or by e-mail at (b) (4).

Thank you in advance for your time and interest.

All best,

(b) (4)





(b) (4)



(b) (4)



(b) (4)



**From:** Thomas, Christopher (NIH/NINDS) [E]  
**To:** Hallett, Mark (NIH/NINDS) [E]  
**Subject:** RE: PRESS REQUEST: Surgery for Neurological Conditions  
**Date:** Monday, March 12, 2018 10:40:00 AM  
**Attachments:** image001.png

---

Hi Mark,  
HHS has approved the interview.  
Best,  
Chris

**From:** (b) (4)  
**Sent:** Sunday, March 11, 2018 4:11 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>  
**Cc:** NINDS Press Team <NINDSPressTeam@ninds.nih.gov>  
**Subject:** Re: PRESS REQUEST: Surgery for Neurological Conditions

Thank you! My editor identified you for DBS. It would be great if you can speak to FUS as well, assuming the Press Office agrees.

Please keep me posted.

(b) (4)

---

**From:** "Hallett, Mark (NIH/NINDS) [E]" <hallettm@ninds.nih.gov>  
**Date:** Sunday, March 11, 2018 at 7:13 AM  
**To:** (b) (4)  
**Cc:** NINDS Press Team <NINDSPressTeam@ninds.nih.gov>  
**Subject:** RE: PRESS REQUEST: Surgery for Neurological Conditions

I would not consider myself a real expert, but I could respond about DBS and FUS to some extent. In any event, I am not permitted to do this unless I get permission from NIH. I will copy the Press Office and see if this will work.....

Mark Hallett, M.D., D.M.(hon)  
Chief, Human Motor Control Section, NINDS  
NIH, Building 10, Room 7D37  
10 Center Dr MSC 1428  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

---

**From:** (b) (4)  
**Sent:** Sunday, March 11, 2018 1:36 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>

**Subject:** PRESS REQUEST: Surgery for Neurological Conditions

Dear Dr. Hallet –

I'm a journalist in (b) (4) and I'm writing a story for (b) (4) about surgical procedures for neurological conditions. In addition to providing an overview of surgery for neurological conditions such as epilepsy, Parkinson's Disease and movement disorders, we would like to hone in on specific procedures – the benefits and risks, what readers should know before they undergo surgery and what the long-term outcomes are for patients undergoing these procedures. Among the procedures we plan to highlight: (b) (4)

(b) (4)

Please let me know if you're interested in participating in a telephone interview on the subject, and when you might be available to chat.

Many thanks,

(b) (4)



(b) (4)

**From:** [Hallett, Mark \(NIH/NINDS\) \[E\]](#)  
**To:** [Thomas, Christopher \(NIH/NINDS\) \[E\]](#)  
**Subject:** RE: Invitation to participate in a neurology podcast  
**Date:** Friday, March 9, 2018 4:53:33 PM

---

thanks

Mark Hallett, M.D., D.M.(hon)  
Chief, Human Motor Control Section, NINDS  
NIH, Building 10, Room 7D37  
10 Center Dr.MSC 1428  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

---

**From:** Thomas, Christopher (NIH/NINDS) [E]  
**Sent:** Friday, March 09, 2018 1:39 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** RE: Invitation to participate in a neurology podcast

Hi Mark,  
HHS approved the interview.  
Best,  
Chris

---

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Thursday, March 08, 2018 9:13 PM  
**To:** NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>  
**Subject:** FW: Invitation to participate in a neurology podcast

Is this okay?  
Thanks.....mark

**From:** [REDACTED] (b) (4)  
**Sent:** Thursday, March 08, 2018 7:25 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** Re: Invitation to participate in a neurology podcast

Hi Dr. Hallett,

I apologize for a second email. I hope you will consider this interview as part of this educational program I have built for medical trainees.

Thank you.



(b) (4)

---

(b) (4)

On Sun, Feb 11, 2018 at 5:18 PM, (b) (4) wrote:

Hi Dr. Hallett,

My name is (b) (4) and I am the Producer of the (b) (4) and the NIH (b) (4). I am writing to you in regard to an upcoming episode of the (b) (4) podcast which will focus broadly on the subject of fMRI in conversion disorder.

As an expert in motor planning circuitry and functional neuroimaging, your contribution to this episode would be invaluable to the program. Briefly, the (b) (4) podcast is a (b) (4) audio program that can be accessed on iTunes, GooglePlay, Stitcher, and a variety of other media, and our episodes are downloaded 6-8,000 times per month by medical students, residents and fellows, as well as practicing physicians around the world. To date, we have published over (b) (4) episodes, with over (b) (4) unique downloads.

This April 1st, I plan to release a show concurrent with the theme of April Fool's Day. Conversion disorder and other disorders of somatization have always interested me, and I think this would be a great opportunity to educate trainees on functional imaging, and in particular, how fMRI may inform us about psychosomatic disorders.

I hope you will consider participating in this interview. Typically, interviews are conducted over half an hour via Skype, and the respondents are provided with the questions well in advance.

I look forward to your positive response. Thank you for your time.

(b) (4)

---

(b) (4)

**From:** Hallett, Mark (NIH/NINDS) [E]  
**To:** Thomas, Christopher (NIH/NINDS) [E]  
**Subject:** RE: (b) (4) Interview Topics  
**Date:** Monday, February 26, 2018 8:59:41 PM

---

ok

Mark Hallett, M.D., D.M.(hon)  
 Chief, Human Motor Control Section, NINDS  
 NIH, Building 10, Room 7D37  
 10 Center Dr MSC 1428  
 Bethesda, MD 20892-1428  
 Tel: 301-496-9526  
 Fax: 301-480-2286  
 email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** Thomas, Christopher (NIH/NINDS) [E]  
**Sent:** Monday, February 26, 2018 3:40 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** RE: (b) (4) Interview Topics

Hi Mark,  
 The reporter canceled this week's interview. She may be in the DC area next week. I'll let you know more.  
 Best,  
 Chris

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Friday, February 23, 2018 11:46 AM  
**To:** Thomas, Christopher (NIH/NINDS) [E] <[christopher.thomas@nih.gov](mailto:christopher.thomas@nih.gov)>  
**Subject:** RE: (b) (4) Interview Topics

OK. The expert in NYC is Dr. Stan Fahn at Columbia. He is the father of the whole movement disorder field and this is one of his interests.....mark,

Mark Hallett, M.D., D.M.(hon)  
 Chief, Human Motor Control Section, NINDS  
 NIH, Building 10, Room 7D37  
 10 Center Dr MSC 1428  
 Bethesda, MD 20892-1428  
 Tel: 301-496-9526  
 Fax: 301-480-2286  
 email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** Thomas, Christopher (NIH/NINDS) [E]  
**Sent:** Friday, February 23, 2018 11:37 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** (b) (4) Interview Topics

Hi Mark,  
Below are the topics the (b) (4) reporter would like to cover with you.  
Is there an expert FND expert in the New York City area?  
Best,  
Chris

---

**From:** (b) (4)  
**Sent:** Wednesday, February 21, 2018 4:34 PM  
**To:** Thomas, Christopher (NIH/NINDS) [E] <[christopher.thomas@nih.gov](mailto:christopher.thomas@nih.gov)>  
**Subject:** Re: Cuba query.

Dear Chris,

Per our call, here are two pieces we'd ask Dr. Hallett to comment on:

(b) (4)

We're also hoping for a basic explanation of mass hysteria, and maybe some instances of when it's appeared to happen. We'd also be curious in terms of medical sleuthing how one might go about concluding this phenomena took place, and the challenges of figuring out mystery illnesses in general.

Thank you,

(b) (4)

**From:** Thomas, Christopher (NIH/NINDS) [E]  
**To:** Hallett, Mark (NIH/NINDS) [E]  
**Subject:** Talk w/ (b) (4) about Cuba?  
**Date:** Friday, February 16, 2018 12:41:00 PM

---

Hi Mark,

Next week, would you be willing to be interviewed on camera by the (b) (4) about neurological problems reported by the U.S. diplomats in Cuba (see email below)?

If so, when would you be free and is there some time today we could chat over the phone about it?

I'm working from home today. So feel free to call my cell phone or ask me to call.

Thanks,

Chris

Cell: (b) (6)

**Christopher G. Thomas, Ph.D.**

Science Writer, Press Team Lead

Office of Communications and Public Liaison

National Institute of Neurological Disorders & Stroke

National Institutes of Health

Building 31, Room 8A07

31 Center Drive MSC 2510

Bethesda, MD 20892-2510

Phone: (301) 435-2264

Fax: (301) 402-2186

Email: [thomaschr@ninds.nih.gov](mailto:thomaschr@ninds.nih.gov)

---

**From:** (b) (4)  
**Sent:** Tuesday, February 13, 2018 12:04 PM  
**To:** Wojtowicz, Emma (NIH/OD) [E] <[emma.wojtowicz@nih.gov](mailto:emma.wojtowicz@nih.gov)>  
**Subject:** Cuba query.

Hi Emma,

Per our chat just now, I'm with the video team and we're working on a documentary on US-Cuba relations, one part of which looks at the American diplomats impacted (some say attack, some say not), and I know, for example, that Dr. Mark Hallett has talked about the mass hysteria aspect of this before. We also know that another possibility discussed has been a (b) (4) type of situation. Is anyone at NIH able to discuss this in any way?

In terms of deadline, we're actually in DC next week, so if someone is available then, that would be fantastic.

Let me know and thank you,

(b) (4)





**From:** Alter, Katharine (NIH/CC/PDB) [E]  
**To:** Hallett, Mark (NIH/NINDS) [E]; Ehrlich, Debra (NIH/NINDS) [E]; Karp, Barbara (NIH/NINDS) [E]; Freimuth, Molly (NIH/CC/OC) [E]; NINDS Press Team  
**Cc:** Nath, Avindra (NIH/NINDS) [E]; Ahmad, Omar (NIH/NINDS) [E]  
**Subject:** RE: FYI Interview request: Dystonia and the use of Botulinum Toxin/Botox  
**Date:** Thursday, January 18, 2018 5:57:29 PM

---

OK

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Thursday, January 18, 2018 5:51 PM  
**To:** Alter, Katharine (NIH/CC/PDB) [E] <kalter@cc.nih.gov>; Ehrlich, Debra (NIH/NINDS) [E] <debra.ehrlich@nih.gov>; Karp, Barbara (NIH/NINDS) [E] <karpb@ninds.nih.gov>; Freimuth, Molly (NIH/CC/OC) [E] <molly.freimuth@nih.gov>; NINDS Press Team <NINDSPressTeam@ninds.nih.gov>  
**Cc:** Nath, Avindra (NIH/NINDS) [E] <avindra.nath@nih.gov>; Ahmad, Omar (NIH/NINDS) [E] <omar.ahmad@nih.gov>  
**Subject:** RE: FYI Interview request: Dystonia and the use of Botulinum Toxin/Botox

Thanks, you should just go ahead unless NINDS would like to have someone from NINDS participate.....mark

Mark Hallett, M.D., D.M.(hon)  
 Chief, Human Motor Control Section, NINDS  
 NIH, Building 10, Room 7D37  
 10 Center Dr MSC 1428  
 Bethesda, MD 20892-1428  
 Tel: 301-496-9526  
 Fax: 301-480-2286  
 email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** Alter, Katharine (NIH/CC/PDB) [E]  
**Sent:** Thursday, January 18, 2018 1:19 PM  
**To:** Ehrlich, Debra (NIH/NINDS) [E] <debra.ehrlich@nih.gov>; Karp, Barbara (NIH/NINDS) [E] <karpb@ninds.nih.gov>; Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>; Freimuth, Molly (NIH/CC/OC) [E] <molly.freimuth@nih.gov>; NINDS Press Team <NINDSPressTeam@ninds.nih.gov>  
**Cc:** Nath, Avindra (NIH/NINDS) [E] <avindra.nath@nih.gov>; Ahmad, Omar (NIH/NINDS) [E] <omar.ahmad@nih.gov>  
**Subject:** RE: FYI Interview request: Dystonia and the use of Botulinum Toxin/Botox

Mark et al,

I am fine handling this on my own but also happy to have someone from the NINDS there if you are interested in coming

Katharine

---

**From:** Ehrlich, Debra (NIH/NINDS) [E]  
**Sent:** Thursday, January 18, 2018 8:29 AM  
**To:** Karp, Barbara (NIH/NINDS) [E] <[karpb@ninds.nih.gov](mailto:karpb@ninds.nih.gov)>; Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>; Freimuth, Molly (NIH/CC/OC) [E] <[molly.freimuth@nih.gov](mailto:molly.freimuth@nih.gov)>; NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>; Alter, Katharine (NIH/CC/PDB) [E] <[kalter@cc.nih.gov](mailto:kalter@cc.nih.gov)>  
**Cc:** Nath, Avindra (NIH/NINDS) [E] <[avindra.nath@nih.gov](mailto:avindra.nath@nih.gov)>; Ahmad, Omar (NIH/NINDS) [E] <[omar.ahmad@nih.gov](mailto:omar.ahmad@nih.gov)>  
**Subject:** Re: FYI Interview request: Dystonia and the use of Botulinum Toxin/Botox

I am also in agreement. Happy to join if any additional help or support is desired, otherwise I'm also fine with Katharine doing it.

Best wishes,  
Debra

Debra Ehrlich, MD  
Chief, NIH Parkinson's Disease Clinic  
National Institute of Neurological Disorders and Stroke, NIH  
Building 10, Room 7D37  
10 Center Drive, MSC 1428  
Bethesda, MD 20892  
Tel: 301-443-7888  
Fax: 301-480-2286

---

**From:** "Karp, Barbara (NIH/NINDS) [E]" <[karpb@ninds.nih.gov](mailto:karpb@ninds.nih.gov)>  
**Date:** Wednesday, January 17, 2018 at 8:59 PM  
**To:** "Hallett, Mark (NIH/NINDS) [E]" <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>; "Freimuth, Molly (NIH/CC/OC) [E]" <[molly.freimuth@nih.gov](mailto:molly.freimuth@nih.gov)>; NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>; "Alter, Katharine (NIH/CC/PDB) [E]" <[kalter@cc.nih.gov](mailto:kalter@cc.nih.gov)>  
**Cc:** "Nath, Avindra (NIH/NINDS) [E]" <[avindra.nath@nih.gov](mailto:avindra.nath@nih.gov)>; "Ehrlich, Debra (NIH/NINDS) [E]" <[debra.ehrlich@nih.gov](mailto:debra.ehrlich@nih.gov)>; "Ahmad, Omar (NIH/NINDS) [E]" <[omar.ahmad@nih.gov](mailto:omar.ahmad@nih.gov)>  
**Subject:** Re: FYI Interview request: Dystonia and the use of Botulinum Toxin/Botox

Same for me. I am fine with Katharine handling it but would be willing to participate if she wants.

Barbara I. Karp, MD  
Chair, Combined Neuroscience IRB  
Bld 31; Room B2B32  
National Institutes of Health  
9000 Rockville Pike  
Bethesda, MD 20892

phone: 301-496-0150  
fax: 301-480-2973  
<http://neuroscience.nih.gov/irb>

---

**From:** "Hallett, Mark (NIH/NINDS) [E]" <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Date:** Wednesday, January 17, 2018 at 6:17 PM  
**To:** "Freimuth, Molly (NIH/CC/OC) [E]" <[molly.freimuth@nih.gov](mailto:molly.freimuth@nih.gov)>, NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>  
**Cc:** "Avindra Nath, [E]" <[avindra.nath@nih.gov](mailto:avindra.nath@nih.gov)>, "Ehrlich, Debra (NIH/NINDS) [E]" <[debra.ehrlich@nih.gov](mailto:debra.ehrlich@nih.gov)>, Barbara Karp <[karpb@ninds.nih.gov](mailto:karpb@ninds.nih.gov)>, "Ahmad, Omar (NIH/NINDS) [E]" <[omar.ahmad@nih.gov](mailto:omar.ahmad@nih.gov)>  
**Subject:** RE: FYI Interview request: Dystonia and the use of Botulinum Toxin/Botox

Ok with me to just have Katharine do it. If she wants help from any of us, or if NINDS wants someone from NINDS to participate, I am sure we would be happy to participate.  
 Mark

Mark Hallett, M.D., D.M.(hon)  
 Chief, Human Motor Control Section, NINDS  
 NIH, Building 10, Room 7D37  
 10 Center Dr MSC 1428  
 Bethesda, MD 20892-1428  
 Tel: 301-496-9526  
 Fax: 301-480-2286  
 email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

---

**From:** Freimuth, Molly (NIH/CC/OC) [E]  
**Sent:** Wednesday, January 17, 2018 2:46 PM  
**To:** NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>  
**Cc:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>; Nath, Avindra (NIH/NINDS) [E] <[avindra.nath@nih.gov](mailto:avindra.nath@nih.gov)>; Ehrlich, Debra (NIH/NINDS) [E] <[debra.ehrlich@nih.gov](mailto:debra.ehrlich@nih.gov)>; Karp, Barbara (NIH/NINDS) [E] <[karpb@ninds.nih.gov](mailto:karpb@ninds.nih.gov)>; Ahmad, Omar (NIH/NINDS) [E] <[omar.ahmad@nih.gov](mailto:omar.ahmad@nih.gov)>  
**Subject:** FYI Interview request: Dystonia and the use of Botulinum Toxin/Botox

Good afternoon,

I wanted to flag a request that has come across our plate to speak with our researcher Dr. Katherine Alter, in the Rehabilitation Medicine Department.

More details are below, including the patient that referring the media outlet to Dr. Alter. The patient is on board, and I will work on getting his communications consent form. These are some of the trials he's been a part of:

<https://clinicaltrials.gov/ct2/show/NCT01019343?term=10-N-0009&rank=1>

<https://clinicaltrials.gov/ct2/show/NCT00001208?term=85-N-0195&rank=1>

<https://clinicaltrials.gov/ct2/show/NCT00001367?term=93-N-0202&rank=1>



Dr. Alter said of course, if anyone from NINDS wants to join the filming on Feb. 1, they should since it's a joint collaboration.

She mentioned the names of all of those cc'd – hence why I wanted to flag specifically to them.

Molly

Molly H. Freimuth, MBA  
Media Lead  
Office of Communications and Media Relations  
National Institutes of Health Clinical Center  
[molly.freimuth@nih.gov](mailto:molly.freimuth@nih.gov)  
Office: 301-594-5789  
Cell: (b) (6)

Reporter: (b) (4)

Organization: (b) (4)

Subject: Dystonia and the use of Botulinum Toxin/Botox

Spokesperson: Dr. Katherine Alter, MD, Staff Clinician, NIH Clinical Center

Expected place of publication (print, online, broadcast): broadcast

Expected date of publication/airing: TBD

Expected prominence (e.g. front page, Sunday, evening/morning show, etc.): low

Key messages/talking points:

Dr. Alter will answer questions about the patient's specific condition/symptoms, treatment with Botulinum Toxin and his current regimen (and the use of Botox) and she will describe what dystonia is and the use of botulinum toxin for patients that have dystonia.

Additional information:

(b) (4)

**From:** Hallett, Mark (NIH/NINDS) [E]  
**To:** (b) (4) Thomas, Christopher (NIH/NINDS) [E]  
**Subject:** RE: NIH Interview: Mark Hallett & functional neurological disorders  
**Date:** Friday, January 12, 2018 7:25:35 PM

---

I could talk some time on Monday.....I am free all day.....

Mark Hallett, M.D., D.M.(hon)  
Chief, Human Motor Control Section, NINDS  
NIH, Building 10, Room 7D37  
10 Center Dr.MSC 1428  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
email: hallettm@ninds.nih.gov  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** (b) (4)  
**Sent:** Friday, January 12, 2018 6:37 PM  
**To:** Thomas, Christopher (NIH/NINDS) [E] <christopher.thomas@nih.gov>; Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>  
**Subject:** Re: NIH Interview: Mark Hallett & functional neurological disorders

Thanks so much, Chris! I really appreciate it.

Let me know a good time for you, Dr. Hallett. I assume you're out Monday, but Tuesday would be fine too.

Have a good weekend!

(b) (4)

[Newsletter](#)  
[Website](#)  
[Book](#)

---

**From:** "Thomas, Christopher (NIH/NINDS) [E]" <christopher.thomas@nih.gov>  
**To:** (b) (4); "Hallett, Mark (NIH/NINDS) [E]" <hallettm@ninds.nih.gov>  
**Sent:** Friday, January 12, 2018 4:53 PM  
**Subject:** NIH Interview: Mark Hallett & functional neurological disorders

Hi (b) (4)

Dr. Hallett would be glad to talk with you about functional neurological disorders. To help schedule an interview, I've included him in this message.

Feel free to contact me if you have any further questions etc.

Good luck!  
Chris

Mark Hallett, M.D., senior investigator, NIH's National Institute of Neurological Disorders and Stroke  
Email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
Office Phone: 301-496-9526

(b) (4)

***Christopher G. Thomas, Ph.D.***  
Science Writer, Press Team Lead  
Office of Communications and Public Liaison  
National Institute of Neurological Disorders & Stroke  
National Institutes of Health  
Building 31, Room 8A07  
31 Center Drive MSC 2510  
Bethesda, MD 20892-2510  
Phone: (301) 435-2264  
Fax: (301) 402-2186  
Email: [thomaschr@ninds.nih.gov](mailto:thomaschr@ninds.nih.gov)

**From:** Thomas, Christopher (NIH/NINDS) [E]  
**To:** Hallett, Mark (NIH/NINDS) [E]  
**Subject:** RE: Talk w/ (b) (4) Reporter about Functional Neurological Disorders?  
**Date:** Friday, January 12, 2018 5:47:00 PM

---

Hi Mark,

Great! HHS approved the interview. I assured them that you would strictly talk about functional neurological disorders and not about Cuba etc.

In a moment, I'll send you and the reporter an introductory email to help you schedule the interview.

Good luck!

Chris

---

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Friday, January 12, 2018 4:49 PM  
**To:** Thomas, Christopher (NIH/NINDS) [E] <christopher.thomas@nih.gov>  
**Subject:** RE: Talk w/ (b) (4) Reporter about Functional Neurological Disorders?

Sure, I would be willing to do it.....mark

Mark Hallett, M.D., D.M.(hon)  
 Chief, Human Motor Control Section, NINDS  
 NIH, Building 10, Room 7D37  
 10 Center Dr MSC 1428  
 Bethesda, MD 20892-1428  
 Tel: 301-496-9526  
 Fax: 301-480-2286  
 email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

---

**From:** Thomas, Christopher (NIH/NINDS) [E]  
**Sent:** Friday, January 12, 2018 4:47 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** Talk w/ (b) (4) Reporter about Functional Neurological Disorders?

Hi Mark,

A reporter from (b) (4) is interested speaking with an expert in functional neurological disorders (see below). As he says, it's in lieu of the Cuba hearing loss story but that he doesn't need someone to comment on that.

Would you be willing to talk with him? His deadline is early next week.

If not, do have a recommendation on another expert?

Best,

Chris

**Christopher G. Thomas, Ph.D.**



Science Writer, Press Team Lead  
Office of Communications and Public Liaison  
National Institute of Neurological Disorders & Stroke  
National Institutes of Health  
Building 31, Room 8A07  
31 Center Drive MSC 2510  
Bethesda, MD 20892-2510  
Phone: (301) 435-2264  
Fax: (301) 402-2186  
Email: [thomaschr@ninds.nih.gov](mailto:thomaschr@ninds.nih.gov)

**From:** [REDACTED] (b) (4)  
**Sent:** Friday, January 12, 2018 4:38 PM  
**To:** Thomas, Christopher (NIH/NINDS) [E] <[christopher.thomas@nih.gov](mailto:christopher.thomas@nih.gov)>  
**Subject:** Re: Media Inquiry

The story is nominally about the Cuba attacks, but I don't need anyone to comment on that.

What I need is someone who can explain in more detail what functional neurological disorders are--what are the pathways, how do they work, how open to treatment are they, how is that framework different from the psychosomatic framework. That sort of thing.

I've been researching this stuff for the last few years, and recently [REDACTED] (b) (4) out about cultural syndromes, which are in the same category. I'm wanting to delve deeper into the actual mechanism.

[REDACTED] (b) (4)

[Newsletter](#)  
[Website](#)  
[Book](#)

**From:** [REDACTED] (b) (4)  
**Sent:** Friday, January 12, 2018 10:34 AM  
**To:** NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>  
**Subject:** Media Inquiry

Hello,

I'm a writer for [REDACTED] (b) (4) magazine, and [REDACTED] (b) (4)  
[REDACTED] (b) (4) | wondering if would be possible to talk to Dr. Mark Hallett  
about the finer points of functional neurologic disorders some time this afternoon or

C06661411

early next week. If so that would be very helpful.

Thanks much,

 (b) (4)

Newsletter

Website

Book

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** 21 Oct 2018 19:45:30 +0000  
**To:** Clare Wilson  
**Cc:** NINDS Press Team;Finnell, Katy (NIH/NINDS) [E];Hicks, Elizabeth (NIH/NINDS) [C]  
**Subject:** RE: New Scientist article on functional neurological disorders

I can speak with you only after review of the situation by the NINDS Press Team, whom I have copied. If it will work, someone in my office will arrange the time with you.....

Mark Hallett, MD, DM (hon)  
Human Motor Control Section  
Medical Neurology Branch  
National Institute of Neurological Disorders and Stroke  
National Institutes of Health  
Building 10, Room 7D37  
10 Center Drive  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
Email: hallettm@ninds.nih.gov

---

**From:** Clare Wilson <Clare.Wilson@newscientist.com>  
**Sent:** Saturday, October 20, 2018 6:32 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>  
**Subject:** Re: New Scientist article on functional neurological disorders

Thanks for getting back to me and I'm sorry to have bothered you when you're travelling. Would there be a day after your travels when you might be able to spare 20 minutes or so please? I have spoken with several UK doctors so far (I am based in London) but it would be great to get a picture of treatment of FNDs in the US too.

Many thanks

Clare

---

**Clare Wilson**

Medical reporter

New Scientist

---

+44 (0)7880 785 499

+44 (0)20 8288 8363

[www.newscientist.com](http://www.newscientist.com)

---

**From:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Sent:** 20 October 2018 08:36  
**To:** Clare Wilson  
**Subject:** RE: New Scientist article on functional neurological disorders

Sorry [REDACTED] (b) (6) through mid-next week.....

Mark Hallett, MD, DM (hon)  
Human Motor Control Section  
Medical Neurology Branch  
National Institute of Neurological Disorders and Stroke  
National Institutes of Health  
Building 10, Room 7D37  
10 Center Drive  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
Email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)

---

**From:** Clare Wilson <[Clare.Wilson@newscientist.com](mailto:Clare.Wilson@newscientist.com)>  
**Sent:** Friday, October 19, 2018 4:50 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** New Scientist article on functional neurological disorders

Dear Dr Hallett - I'm a journalist at New Scientist magazine and I'm writing a feature-length article about functional neurological disorders. Do you have some time for a chat by phone about your work in this area please? If that's OK it would ideally need to be some time in the next few days, if possible,

Many thanks, in advance, if you're able to help.

Best wishes

Clare Wilson

---

**Clare Wilson**

Medical reporter

New Scientist

---

+44 (0)7880 785 499

+44 (0)20 8288 8363

[www.newscientist.com](http://www.newscientist.com)

---

[New Scientist | Science news and science articles from New Scientist](http://www.newscientist.com)

[www.newscientist.com](http://www.newscientist.com)

Science news and science articles from New Scientist

---



**From:** Gallagher, Alissa (NIH/NINDS) [E]  
**Sent:** 29 Oct 2018 14:58:18 +0000  
**To:** Koroshetz, Walter (NIH/NINDS) [E]; Adams, Amy (NIH/NINDS) [E]; Scott, Paul (NIH/NINDS) [E]  
**Subject:** NBC News article about embassy attacks

FYI, article in NBC News about the embassy attacks: [Evacuated after 'health attacks' in Cuba and China, diplomats face new ordeals in U.S.](#)

Thanks,  
Alissa

Not Responsive

---

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Tuesday, September 11, 2018 11:58 AM  
**To:** NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>; Burklow, John (NIH/OD) [E] <[burklowj@od.nih.gov](mailto:burklowj@od.nih.gov)>  
**Subject:** FW: off-the-record question

Please advise how to respond.  
I will be talking with John at 1:30 anyway.  
Mark

**From:** Dan Hurley <[hurleydan1@gmail.com](mailto:hurleydan1@gmail.com)>  
**Sent:** Tuesday, September 11, 2018 11:50 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Subject:** off-the-record question

Hi Dr. Hallett: I have been speaking to many of your admirers in functional neurologic disorders, including Alberto Espay, Kathrin LaFaver, Vesper Ramos and of course Jon Stone.

Yesterday, I was told by an NIH official that you are among a group of NIH physician-scientists who are evaluating the diplomatic personnel who have developed neurologic symptoms while serving in Cuba or China. Strictly off the record, can you confirm or deny that? I was surprised only because the State Department has been adamant in sticking to the claim that an "attack" occurred, and your views expressed in the Guardian, like the views expressed to me by the other experts in functional disorders, call into question the notion of such an "attack." It's also been striking to me that the diplomats have all been sent by the State Department to UPenn, where Dr. Smith and colleagues have doubled down on their view that "brain damage" occurred as a result of an organic, external force. Some have expressed the view that this insistence on there being a mysterious, unknown, intentionally harmful cause of the diplomats' symptoms may actually be exacerbating those symptoms.

As you know, much of news reporting relies on off-the-record information from sources who ask not to be identified in print, and I can guarantee you confidentiality regarding anything you can share. I am doing a very deep dive into the science of functional disorders. It would be vitally important to know if in

fact the possibility of a functional disorder at the root of these symptoms is being explored by an expert panel of NIH physician-scientists. Thank you, Dan Hurley

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** 11 Sep 2018 15:58:16 +0000  
**To:** NINDS Press Team;Burklow, John (NIH/OD) [E]  
**Subject:** FW: off-the-record question

Please advise how to respond.  
I will be talking with John at 1:30 anyway.  
Mark

**From:** Dan Hurley <hurleydan1@gmail.com>  
**Sent:** Tuesday, September 11, 2018 11:50 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>  
**Subject:** off-the-record question

Hi Dr. Hallett: I have been speaking to many of your admirers in functional neurologic disorders, including Alberto Espay, Kathrin LaFaver, Vesper Ramos and of course Jon Stone.

Yesterday, I was told by an NIH official that you are among a group of NIH physician-scientists who are evaluating the diplomatic personnel who have developed neurologic symptoms while serving in Cuba or China. Strictly off the record, can you confirm or deny that? I was surprised only because the State Department has been adamant in sticking to the claim that an "attack" occurred, and your views expressed in the Guardian, like the views expressed to me by the other experts in functional disorders, call into question the notion of such an "attack." It's also been striking to me that the diplomats have all been sent by the State Department to UPenn, where Dr. Smith and colleagues have doubled down on their view that "brain damage" occurred as a result of an organic, external force. Some have expressed the view that this insistence on there being a mysterious, unknown, intentionally harmful cause of the diplomats' symptoms may actually be exacerbating those symptoms.

As you know, much of news reporting relies on off-the-record information from sources who ask not to be identified in print, and I can guarantee you confidentiality regarding anything you can share. I am doing a very deep dive into the science of functional disorders. It would be vitally important to know if in fact the possibility of a functional disorder at the root of these symptoms is being explored by an expert panel of NIH physician-scientists. Thank you, Dan Hurley

**From:** Gallagher, Alissa (NIH/NINDS) [E]  
**Sent:** 11 Sep 2018 14:51:09 +0000  
**To:** Koroshetz, Walter (NIH/NINDS) [E]  
**Subject:** RE: interesting article

Indeed...

---

**From:** Koroshetz, Walter (NIH/NINDS) [E]  
**Sent:** Tuesday, September 11, 2018 10:10 AM  
**To:** Gallagher, Alissa (NIH/NINDS) [E] <alissa.gallagher@nih.gov>  
**Subject:** interesting article

<https://www.nbcnews.com/news/latin-america/u-s-officials-suspect-russia-mystery-attacks-diplomats-cuba-china-n908141>

walter  
Walter J. Koroshetz, M.D.  
Director, National Institute of Neurological Disorders and Stroke



**From:** Gallagher, Alissa (NIH/NINDS) [E]  
**Sent:** 11 Sep 2018 13:36:51 +0000  
**To:** Koroshetz, Walter (NIH/NINDS) [E]; Adams, Amy (NIH/NINDS) [E]; Mott, Meghan (NIH/NINDS) [E]  
**Subject:** News

This NBC article posted this morning: [U.S. officials suspect Russia in mystery 'attacks' on diplomats in Cuba, China](#). It mentions the Aug. 14 meeting that included officials from NIH.

Thanks,  
Alissa

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** 10 Sep 2018 13:22:51 +0000  
**To:** McMakin, Barbara (NIH/NINDS) [E]  
**Cc:** Gallagher, Alissa (NIH/NINDS) [E]; Warren, Margo (NIH/NINDS) [E]  
**Subject:** RE: TV Interview in Atlanta

The Rounds that I am giving there relate to the treatment of dystonia, mostly hand dystonia. So I could talk about that, writer's cramp and musician's cramp and various treatments, pointing out particularly botulinum toxin.....mark

Mark Hallett, M.D., D.M.(hon)  
Chief, Human Motor Control Section, NINDS  
NIH, Building 10, Room 7D37  
10 Center Dr MSC 1428  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

---

**From:** McMakin, Barbara (NIH/NINDS) [E]  
**Sent:** Monday, September 10, 2018 8:57 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Cc:** Gallagher, Alissa (NIH/NINDS) [E] <[alissa.gallagher@nih.gov](mailto:alissa.gallagher@nih.gov)>; Warren, Margo (NIH/NINDS) [E] <[warrenm@ninds.nih.gov](mailto:warrenm@ninds.nih.gov)>  
**Subject:** RE: TV Interview in Atlanta

Hi Dr. Hallett,

Thank you for your email. We wanted to follow-up with you regarding this media request. Have you given any thought to the topic you would like to discuss for the PBS show? Please let us know what you are planning to talk about and we can send through a clearance request to HHS.

Best,  
Barbara

***Barbara I. McMakin***  
Science Writer  
Office of Communications and Public Liaison  
National Institute of Neurological Disorders & Stroke  
National Institutes of Health  
Building 31, Room 8A07  
31 Center Drive MSC 2540  
Bethesda, MD 20892-2540  
Main Office Line: (301) 496-5751  
Direct Line: (301) 435-7747

Email: [mcmakinbi@ninds.nih.gov](mailto:mcmakinbi@ninds.nih.gov)



---

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Friday, September 07, 2018 9:03 PM  
**To:** Blair, Douglas S. <[douglas.s.blair@emory.edu](mailto:douglas.s.blair@emory.edu)>  
**Cc:** Watson, Jaye <[jaye.watson@emory.edu](mailto:jaye.watson@emory.edu)>; Borich, Michael R. <[michael.borich@emory.edu](mailto:michael.borich@emory.edu)>; NINDS Press Team <[NINDSPressTeam@ninds.nih.gov](mailto:NINDSPressTeam@ninds.nih.gov)>  
**Subject:** RE: TV Interview in Atlanta

Happy to do it if (1) it fits with my schedule (arranged by Dr. Borich) and (2) if the NINDS Press office approves as well. I have copied both.....mark hallett

---

**From:** Blair, Douglas S. <[douglas.s.blair@emory.edu](mailto:douglas.s.blair@emory.edu)>  
**Sent:** Friday, September 7, 2018 10:42 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Cc:** Watson, Jaye <[jaye.watson@emory.edu](mailto:jaye.watson@emory.edu)>  
**Subject:** TV Interview in Atlanta  
**Importance:** High

Good morning, Dr. Hallett,

My name is Douglas Blair and I am a Senior Communications Manager at the Emory Brain Health Center, which includes the Department of Rehabilitation Medicine where you will be giving a grand rounds lecture next Wednesday.

Several months ago, we were offered a show on PBS in Georgia to feature our stories at brain health, and it launches in 8 weeks. All the stories will feature the brain and mind -- and the majority of content is from Emory faculty and patients. The show features patient centered stories that highlight treatment, the latest breakthroughs, and research. The show will be hosted by Jaye Watson (cc'd), who is a career broadcast journalist with NBC, and was hired last year to tell video stories for Emory Brain Health.

We think it's a good idea to also hear from other brain experts around the country in the show. Collaboration is an important part of research, so the more voices in the show, the better. Leadership at PBS in Georgia believe the show will spread around the country. That is certainly our hope.

I'm hoping you are available for a brief interview before or after grand rounds this coming Wednesday. The topic could be your choice. Whatever you decide to speak about will be distilled to approximately 60-75 seconds (yes, short). Some of the stories in the show are ten

minutes long but those are ones that involve patients and procedures or treatments and where we follow someone over a period of time.

The audience is not your peers, but regular people, viewers at home, so whatever you would talk about would need to be a layman's version. The PBS audience is smart and educated and interested in a deeper understanding of the brain and mind.

We have shorter segments throughout the show that give viewers 'nuggets' of information – where we won't need video outside of your interview – like why we crave carbs and fats, or why car vibrations induce drowsiness, or what we are learning about concussion research/dbs/alzheimer's/als/sleep/parkinson's/mental illness/video game addiction/opioid crisis. Yes, it's a broad range of topics under the brain/mind umbrella.

So, if there is something you'd like to talk about with us for a few minutes that you think would be interesting for the show, we can have our photographer and Jaye meet and interview you before or after you speak.

I'm sorry to ask you so late. We just decided to add other brain experts this week, so I checked grand rounds and saw you were coming.

If this is something you're not interested in, no worries. Just let me know either way.

Thank you so much!

Douglas

**Douglas S. Blair, Senior Communications Manager**  
**Emory Brain Health Center | Emory University School of Medicine**  
Office: 404.778.5343, Cell: (b) (6)  
[douglas.s.blair@emory.edu](mailto:douglas.s.blair@emory.edu)

---

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).



**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** 6 Sep 2018 13:06:16 +0000  
**To:** NINDS Press Team  
**Subject:** FW: microwave radiation/health

---

**From:** (b) (4)  
**Sent:** Thursday, September 6, 2018 7:11 AM  
**To:** Hallett, Mark (NIH/NINDS) [E] <hallettm@ninds.nih.gov>  
**Subject:** RE: microwave radiation/health

No problem, thanks for the response. Best, (b) (4)

---

**From:** Hallett, Mark (NIH/NINDS) [E] [<mailto:hallettm@ninds.nih.gov>]  
**Sent:** Wednesday, September 05, 2018 11:30 PM  
**To:** (b) (4)  
**Cc:** (b) (4)  
**Subject:** RE: microwave radiation/health

[EXTERNAL EMAIL]

I apologize, but I am afraid I cannot comment on this issue.

---

**From:** (b) (4)  
**Sent:** Wednesday, September 5, 2018 5:48 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Cc:** (b) (4)  
**Subject:** microwave radiation/health

Dear Dr. Hallett:

Hi, I'm trying to follow up the Cuba diplomats story. There's been much buzz about this since the Times did a piece a few days ago saying microwave weapons might have been used. Do you have any insights on whether an external microwave source is a plausible explanation for symptoms experienced by embassy personnel? Thanks much in advance. Best, (b) (4)



**From:** Gallagher, Alissa (NIH/NINDS) [E]  
**Sent:** 15 Feb 2018 03:05:29 +0000  
**To:** Koroshetz, Walter (NIH/NINDS) [E]; Schor, Nina (NIH/NINDS) [E]; Adams, Amy (NIH/NINDS) [E]; Scott, Paul (NIH/NINDS) [E]; Mott, Meghan (NIH/NINDS) [E]  
**Subject:** FW: BREAKING: Medical Findings In U.S. Government Personnel Reporting Symptoms After Exposure To Sensory Phenomena in Havana, Cuba

FYI, tomorrow's JAMA.

Begin forwarded message:

**From:** "JAMA" <[updates@jamanetwork.org](mailto:updates@jamanetwork.org)>  
**Date:** February 14, 2018 at 6:24:30 PM EST  
**To:** Susan Dambrauskas <[dambrauskass@nhlbi.nih.gov](mailto:dambrauskass@nhlbi.nih.gov)>  
**Subject:** **BREAKING: Medical Findings In U.S. Government Personnel Reporting Symptoms After Exposure To Sensory Phenomena in Havana, Cuba**  
**Reply-To:** "JAMA" <[reply\\_euqbgg\\_pyabhrl@alerts.jamanetwork.com](mailto:reply_euqbgg_pyabhrl@alerts.jamanetwork.com)>


Trouble viewing this email? [Read it Online](#)

Advertisement

# JAMA

## Online First

FEBRUARY 14, 2018



### PRELIMINARY COMMUNICATION

### YOU ALSO MAY LIKE

#### **Neurological Manifestations Among US Government Personnel Reporting Directional Audible and Sensory Phenomena in Havana, Cuba**

Randel L. Swanson II, DO, PhD; Stephen Hampton, MD; Judith Green-McKenzie, MD, MPH; et al

JAMA. Published online February 15, 2018. doi:10.1001/jama.2018.1742

**Editorial:** Neurological Symptoms Among US Diplomats in Cuba

Christopher C. Muth, MD; Steven L. Lewis, MD

---

**EDITORIAL**

**Neurological Symptoms Among US Diplomats in Cuba**

Christopher C. Muth, MD; Steven L. Lewis, MD

*JAMA*. Published online February 15, 2018. doi:10.1001/jama.2018.1780

---

**MEDICAL NEWS & PERSPECTIVES**

**More Questions Raised by Concussion-like Symptoms Found in US Diplomats Who Served in Havana**

Rita Rubin, MA

*JAMA*. Published online February 15, 2018. doi:10.1001/jama.2018.1751



Author Interview: Clinical Findings and Outcomes in US Government Personnel Reporting Directional Sensory Phenomena in Cuba




---

Thank you for subscribing to JAMA Network email alerts. This message was sent to [dambrauskass@nhlbi.nih.gov](mailto:dambrauskass@nhlbi.nih.gov) by [updates@jamanetwork.org](mailto:updates@jamanetwork.org).

To sign up for additional alerts, or to unsubscribe, [click here](#).

To ensure you always receive JAMA Network emails, add the email address [updates@jamanetwork.org](mailto:updates@jamanetwork.org) to your address book.

To unsubscribe by mail, contact:  
The JAMA Network  
AMA Plaza  
330 N Wabash Ave  
Chicago, IL 60611  
Or call (800) 621-8335.



©2018 American Medical Association. All rights reserved.



Advertisement

**From:** Koroshetz, Walter (NIH/NINDS) [E]  
**Sent:** 7 Dec 2017 14:33:01 +0000  
**To:** Hallett, Mark (NIH/NINDS) [E]; McMakin, Barbara (NIH/NINDS) [E]  
**Cc:** Warren, Margo (NIH/NINDS) [E]  
**Subject:** RE: Media inquiry: embassy medical mystery

Yes, we should refer to outside experts. People who have studied ultrasound—Pasko Rakic at Yale studied ultrasound in development in NHP, Andrei Alexandrov chair of neurology at U of Tennessee has studied transcranial ultrasound in stroke patients, Jeff Elias at U of Virginia uses focused ultrasound for treatment of PD. Jamie Tylor studying effects of focused ultrasound on brain ( <https://www.nature.com/articles/d41586-017-05479-7> )- Lots of experts on sound effects on the ear—hearing and balance structure—Charles Lieberman at Mass Eye and Ear Infirmary a Harvard hospital.

Walter

**From:** Hallett, Mark (NIH/NINDS) [E]  
**Sent:** Wednesday, December 06, 2017 4:42 PM  
**To:** McMakin, Barbara (NIH/NINDS) [E] <barbara.mcmakin@nih.gov>; Koroshetz, Walter (NIH/NINDS) [E] <koroshetzw@ninds.nih.gov>  
**Cc:** Warren, Margo (NIH/NINDS) [E] <warrenm@ninds.nih.gov>  
**Subject:** RE: Media inquiry: embassy medical mystery

Difficult request,

(b) (5)  
(b) (5)

(b) (5) I will copy Dr. Koroshetz who might know who would be appropriate.....mark

Mark Hallett, M.D., D.M.(hon)  
Chief, Human Motor Control Section, NINDS  
NIH, Building 10, Room 7D37  
10 Center Dr MSC 1428  
Bethesda, MD 20892-1428  
Tel: 301-496-9526  
Fax: 301-480-2286  
email: [hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)  
[http://intra.ninds.nih.gov/Lab.asp?Org\\_ID=72](http://intra.ninds.nih.gov/Lab.asp?Org_ID=72)

**From:** McMakin, Barbara (NIH/NINDS) [E]  
**Sent:** Wednesday, December 06, 2017 3:37 PM  
**To:** Hallett, Mark (NIH/NINDS) [E] <[hallettm@ninds.nih.gov](mailto:hallettm@ninds.nih.gov)>  
**Cc:** Warren, Margo (NIH/NINDS) [E] <[warrenm@ninds.nih.gov](mailto:warrenm@ninds.nih.gov)>  
**Subject:** Media inquiry: embassy medical mystery

Hi Dr. Hallett,

A reporter from NPR Phoenix is working on a story about the recent neurological symptoms experienced by embassy staffers in Cuba. Specifically, she would like to know how sound affects brain function and

what other causes could lead to white matter changes and cognitive dysfunction. Are there any outside experts that you could recommend for this request?

Thank you,  
Barbara

***Barbara I. McMakin***

Science Writer

Office of Communications and Public Liaison

National Institute of Neurological Disorders & Stroke

National Institutes of Health

Building 31, Room 8A07

31 Center Drive MSC 2540

Bethesda, MD 20892-2540

Main Office Line: (301) 496-5751

Direct Line: (301) 435-7747

Email: [mcmakinbi@ninds.nih.gov](mailto:mcmakinbi@ninds.nih.gov)





**From:** Moundalexis, Athena M  
**Sent:** 4 Apr 2018 14:21:18 +0000  
**To:** Tabak, Lawrence (NIH/OD) [E]  
**Cc:** Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]; Rosenfarb, Charles H; Munoz, Mark L  
**Subject:** RE: Setting up a time to meet

Larry,  
 Thank you. We will reach out to the content experts and get back to you shortly.  
 Athena

Athena Moundalexis MD  
 Regional Medical Manager  
 Western Hemisphere Affairs  
 2401 E Street NW  
 Washington, DC 20121

Office Phone 202 663 3868

**Official - SBU**  
**UNCLASSIFIED**

---

**From:** Tabak, Lawrence (NIH/OD) [E] [mailto:lawrence.tabak@nih.gov]  
**Sent:** Wednesday, April 04, 2018 8:18 AM  
**To:** Moundalexis, Athena M  
**Cc:** Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]  
**Subject:** Setting up a time to meet

Athena,

With this note I am electronically connecting you to Drs. Gilman ([https://www.cc.nih.gov/about/SeniorStaff/james\\_gilman.html](https://www.cc.nih.gov/about/SeniorStaff/james_gilman.html)), Gordon (<https://neuroscience.nih.gov/ninds/Faculty/Profile/joshua-gordon.aspx>), Koroshetz (<https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Directors-Corner>), and Volkow, (<https://www.drugabuse.gov/about-nida/directors-page>) each directors of relevant NIH institutes and centers. They also strongly recommend including Dr. David Brody at USUHS, who also conducts research at NIH (<https://www.usuhs.edu/national/faculty/david-brody-md-phd>). They are prepared to meet with you and Charles Ronsefarb as well as any other relevant content experts to be briefed on the situation discussed yesterday.

They have requested read-ahead materials detailing the medical findings so that they may best prepare.

Dina Simon in my office will coordinate with NIH staff if you could let me know dates/times when you team would be available to meet and where you want the meeting held.

Thanks, and best wishes,  
Larry

Lawrence A. Tabak, DDS, PhD  
Principal Deputy Director, NIH

**From:** Moundalexis, Athena M  
**Sent:** 4 Apr 2018 16:31:07 +0000  
**To:** Tabak, Lawrence (NIH/OD) [E]  
**Cc:** Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]; david.brody@usuhs.edu; Munoz, Mark L; Rosenfarb, Charles H  
**Subject:** RE: Setting up a time to meet  
**Attachments:** (b) (4) Proposal.doc, JPC180001supp1\_prod.pdf, (b) (4) 2018\_pc\_180001.pdf

Hi all,  
 While we are still working on the timing, attached please find some read-ahead materials.  
 For location, would you like us to come to NIH?

Dr. Brody,  
 We would welcome your participation.

Thanks.  
 Athena

**Official**  
**UNCLASSIFIED**

---

**From:** Tabak, Lawrence (NIH/OD) [E] [mailto:lawrence.tabak@nih.gov]  
**Sent:** Wednesday, April 04, 2018 8:18 AM  
**To:** Moundalexis, Athena M  
**Cc:** Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]  
**Subject:** Setting up a time to meet

Athena,

With this note I am electronically connecting you to Drs. Gilman ([https://www.cc.nih.gov/about/SeniorStaff/james\\_gilman.html](https://www.cc.nih.gov/about/SeniorStaff/james_gilman.html)), Gordon (<https://neuroscience.nih.gov/ninds/Faculty/Profile/joshua-gordon.aspx>), Koroshetz (<https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Directors-Corner>), and Volkow, (<https://www.drugabuse.gov/about-nida/directors-page>) each directors of relevant NIH institutes and centers. They also strongly recommend including Dr. David Brody at USUHS, who also conducts research at NIH (<https://www.usuhs.edu/national/faculty/david-brody-md-phd>). They are prepared to meet with you and Charles Ronsefarb as well as any other relevant content experts to be briefed on the situation discussed yesterday.

They have requested read-ahead materials detailing the medical findings so that they may best prepare.

Dina Simon in my office will coordinate with NIH staff if you could let me know dates/times when your team would be available to meet and where you want the meeting held.

C06661409

Thanks, and best wishes,  
Larry

Lawrence A. Tabak, DDS, PhD  
Principal Deputy Director, NIH







(b) (4)



## Supplementary Online Content

Swanson RL, Hampton S, Green-McKenzie J, et al. Neurological manifestations among US government personnel reporting directional audible and sensory phenomena in Havana, Cuba. *JAMA*. doi:10.1001/jama.2018.1742

**eTable 1.** Acute and Subacute Symptom Descriptions

**eTable 2.** Neuropsychological Test Results: Cognitive Domains

**eTable 3.** Neuropsychological Test Results: Effort Testing

**eTable 4.** Neuropsychological Test Results: Mood Functioning

**eTable 5.** Standardized Measures Obtained During Initial Vestibular Physical Therapy Evaluation

**eTable 6.** Caloric Testing Results

**eTable 7.** Vestibular Impairments Identified Requiring Rehabilitation Interventions

**eTable 8.** Standardized Measures Obtained During Initial Neuro-Optometry Evaluation

**eTable 9.** Clinically Significant Oculomotor Impairments Identified Requiring Dedicated Neuro-optometric Rehabilitation

**eTable 10.** Pure Tone Audiometry Results

**eTable 11.** Sleep and Headache Medication Requirements

**eAppendix.** Glossary of Terms

**eReferences**

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Acute and Subacute Symptom Descriptions

Domain	Acute		Subacute	
		n (%)		n (%)
Cognitive / Behavioral	Combined	16 (76)	Combined	19 (90)
	Desire to change location	10 (48)	Cognitive change	13 (62)
	Confusion/Disorientation	8 (38)	Memory trouble	11 (52)
	Agitation/Irritability	6 (29)	Difficulty concentrating	11 (52)
	Desire to cover head/ears	5 (24)	Word finding difficulty	11 (52)
	Fatigue	3 (14)	Fatigue	10 (48)
	Feeling of paralysis	3 (14)	Agitation/Irritability	8 (38)
			Increased time for cognitive tasks	7 (33)
			Errors at work	6 (29)
Balance / Vestibular	Combined	10 (48)	Combined	14 (67)
	Nausea	7 (33)	Dizziness	13 (62)
	Dizziness	5 (24)	Falls	4 (19)
			Nausea	3 (14)
Visual	Combined	2 (10)	Combined	14 (67)
	Visual changes	1 (5)	Visual changes	10 (48)
	Eye pain	1 (5)	Light sensitivity	9 (43)
			Eye strain	7 (33)
			Difficulty focusing vision	6 (29)
Auditory	Combined	10 (48)	Combined	15 (71)
	Ear pain	7 (33)	Tinnitus	12 (57)
	Tinnitus	6 (29)	Hearing change	7 (33)
	Hearing change	1 (5)	Noise sensitivity	5 (24)
			Ear pain	5 (24)
Sleep	Sleep problem	4 (19)	Sleep problem	16 (76)
Headache	Combined	11 (50)	Combined	17 (81)
	Headache	8 (38)	Headache	17 (81)
	Head Pressure	5 (24)	Unilateral jaw pain	2 (10)
	Unilateral jaw pain	1 (5)		
Overall	Combined acute	21 (100)	Combined subacute	21 (100)
Acute – during or hours following exposure, Subacute – days to weeks following exposure Developed from patient descriptions of symptoms in acute and subacute period following exposure during evaluations at the University of Pennsylvania. Clinical interviews were open-ended, therefore lack of a particular symptom was not systematically verified				

**eTable 2. Neuropsychological Test Results: Cognitive Domains (n=6)**

	Case					
	4	9	11	13	15	20
<b>Auditory Attention and Working Memory</b>						
Digit Span Forward	50	84	9	91	50	98
Digit Span Backward	63	63	50	95	16	95
Digit Span Sequencing	37	37	50	95	37	75
Arithmetic	91	50	37	98	25	75
Letter-Number Sequencing	63	50	63	99	37	50
<b>Visual Working Memory</b>						
Symbol Span	63	50	84	75	63	95
<b>Auditory and Visual Memory</b>						
Logical Memory I	84	9	75	91	50	50
Logical Memory II	63	16	37	95	50	50
Verbal Paired Associates I	95	37	91	98	63	63
Verbal Paired Associates II	91	37	91	95	50	50
Designs I	91	9	50	84	91	84
Designs II	91	25	63	91	75	75
Visual Reproduction I	75	50	25	98	16	63
Visual Reproduction II	91	36	75	95	25	50
Rey-Osterrieth Complex Figure: 3-minute delay	95	15	<10	65	40	<10
California Verbal Learning Test – II: Trials 1 – 5	84	88	84	97	95	95
California Verbal Learning Test – II: Long Delay	63	84	50	94	25	<1
<b>Visual-Spatial Perception and Visual-Motor Construction</b>						
Judgment of Line Orientation	>86	72	56	>86	40	2
Rey-Osterrieth Complex Figure – copy	100	<10	<10	20	90	60
Block Design	91	63	16	91	75	75
<b>Motor Functions</b>						
Grooved Pegboard: Dominant	44	16	<1	88	19	<1
Grooved Pegboard: Non-Dominant	30	16	2	88	9	50
<b>Language Functioning</b>						
Boston Diagnostic Aphasia Examination: Boston Naming Test	88	50	19	7	25	65
Boston Diagnostic Aphasia Examination: Complex Ideational Material	58	50	19	50	50	50
Vocabulary	63	63	75	84	63	75
<b>Executive Functions</b>						
Controlled Oral Word Association: FAS	96	39	88	9	58	96
Animal Naming	58	55	19	4	60	60
Trail Making Test: Part A	21	65	88	82	97	<1
Trail Making Test: Part B	25	34	19	30	65	<1
Ruff Figural Fluency Test: Total Designs	61	32	29	81	21	59
Ruff Figural Fluency Test: Perseverative Errors	63	64	19	52	63	63
<b>Processing Speed</b>						
Coding	63	37	37	91	84	16
Symbol Search	63	25	63	37	84	2
<b>Academic Achievement</b>						
Wide Range Achievement Test-4, Word Reading	47	50	61	68	63	61
<b>Reasoning</b>						
Similarities	63	63	37	95	50	84
Matrix Reasoning	84	75	50	75	75	63
Visual Puzzles	95	84	5	98	63	75

Percentile scores shown. Bold highlighting denotes abnormality or <40<sup>th</sup> percentile<sup>1,3</sup>

© 2018 American Medical Association. All rights reserved.



**Table 3. Neuropsychological Test Results: Effort Testing (n=6)**

	Case					
	4	9	11	13	15	20
<b>Effort</b>						
Test of Memory Malinger						
Trial 1	50	50	50	50	42	41
Trial 2	50	50	50	50	50	50
Rey 15-Item Visual Memory Test	15	15	15	15	12	15
<i>Values listed are all raw values, not percentiles</i>						
<i>- For the Test of Memory Malinger, <sup>4-6</sup> normal is &gt;26 on trial 1 and &gt;45 on Trial 2</i>						
<i>- For Rey 15-Item Visual Memory Test, <sup>7-11</sup> a score of &lt;9 is interpreted as a lack of effort</i>						

**Table 4. Neuropsychological Test Results: Mood Functioning (n=6)**

	Case					
	4	9	11	13	15	20
<b>Mood Functioning<sup>12-17</sup></b>						
Beck Depression Inventory-II	3	17	24	12	11	16
	(Min)	(Mild)	(Mod)	(Min)	(Min)	(Mild)
Beck Anxiety Inventory-Revised	2	2	14	10	5	10
	(Min)	(Min)	(Mild)	(Mild)	(Min)	(Mild)
Brief Mood Survey						
Depression	0	2	7	3	3	3
		(Bord)	(Mod)	(Mild)	(Mild)	(Mild)
Suicidal Urges	0	0	0	0	0	0
Anxiety	1	3	11	3	4	5
	(Bord)	(Mild)	(Severe)	(Mild)	(Mild)	(Mild)
Panic	ND	0	2	1	ND	0
			(Bord)	(Bord)		
Anger	1	11	13	4	4	4
	(Bord)	(Severe)	(Severe)	(Mild)	(Mild)	(Mild)
Post-Traumatic Stress Disorder Checklist - 5 (Cutoff score 33)	1	36	49	23	16	23
Frontal Systems Behavior Scale (Before/After Injury)						
Apathy	41/46	43/77	53/92	47/69	42/68	48/66
Disinhibition	36/44	57/67	49/55	50/66	39/43	37/45
Executive Dysfunction	41/45	39/67	41/76	44/56	46/68	47/75
Total	37/44	44/74	47/74	46/64	41/62	43/65
<i>Values listed are all raw values, not percentiles</i>						
<i>Bold highlighting denotes abnormality</i>						
<i>Abbreviations: Minimal (Min), Borderline (Bord), Not done (ND)</i>						

© 2018 American Medical Association. All rights reserved.

**eTable 5.** Standardized Measures Obtained During Initial Vestibular Physical Therapy Evaluation

Case	Self-Reported Measures		Objective Measures		
	DHI	ABC	FGA	BESS	SOT
1	<b>38</b>	---	<b>29</b>	<b>39</b>	<b>41</b>
2	<b>18</b>	90	<b>29</b>	<b>7</b>	<b>78</b>
4	<b>38</b>	84	<b>28</b>	<b>24</b>	<b>71</b>
5	<b>38</b>	84	<b>23</b>	<b>30</b>	<b>59</b>
6	<b>50</b>	<b>64</b>	<b>20</b>	<b>42</b>	<b>78</b>
8	<b>10</b>	88	<b>29</b>	<b>30</b>	<b>45</b>
9	<b>24</b>	76	<b>27</b>	<b>41</b>	<b>43</b>
10	<b>56</b>	76	<b>24</b>	<b>34</b>	<b>73</b>
11	<b>60</b>	76	<b>28</b>	<b>23</b>	<b>52</b>
12	---	---	<b>30</b>	<b>16</b>	<b>68</b>
13	<b>26</b>	86	<b>21</b>	<b>30</b>	<b>48</b>
15	<b>20</b>	---	<b>29</b>	<b>16</b>	<b>61</b>
16	<b>24</b>	93	<b>25</b>	<b>50</b>	<b>UTC</b>
17	<b>58</b>	<b>61</b>	<b>18</b>	<b>UTC</b>	<b>UTC</b>
18	<b>30</b>	88	<b>30</b>	<b>14</b>	<b>45</b>
20	<b>60</b>	79	<b>29</b>	<b>41</b>	<b>20</b>
21	<b>18</b>	86	<b>26</b>	<b>29</b>	<b>56</b>

**Normative values**

- DHI<sup>18</sup>: Mild (0-30), Moderate (31-60), Severe (61-100) vestibular dysfunction
- ABC<sup>19</sup>: Score < 67% indicates a risk of falling
- FGA<sup>20</sup>: Normal is 30/30
- BESS<sup>21</sup>: Normative values used based on Iverson et al 2013<sup>22</sup>, yielding a categories (superior, above average, broadly normal, below average, poor, and very poor) based on age and sex. Scored 0-60, with higher scores indicating increased static balance impairment.
- SOT<sup>23</sup>: Cut off was 70 for equilibrium score for all patients in the age group tested
- **Bold highlighting denotes abnormality**

-Abbreviations: Dizziness Handicap Index (DHI); Activities Balance Confidence Scale (ABC); Functional Gait Assessment (FGA); Balance Error Scoring System (BESS); Neurocom Balance Manager Sensory Organization test (SOT), Unable to complete (UTC)



**eTable 6. Caloric Testing Results**

Case	Cool		Warm		RVR*	
	Right	Left	Right	Left	%	R/L
1	35	33				
5	23	20				
8	34	22	27	24	7	L
9	20	20				
10	9	3	12	4	<b>50</b>	<b>L</b>
11	24	13	19	7	<b>37</b>	<b>L</b>
13	12	22	22	28		
15	28	17	38	20	<b>28</b>	<b>L</b>
16	39	48	51	62	10	R
17	18	22				
18	19	20				
20	37	8	63	12	<b>67</b>	<b>L</b>
21	42	35				

Normal Values: RVR threshold is <25% asymmetry. Above 25% asymmetry is diagnostic for a unilateral peripheral vestibular lesion.<sup>24-26</sup>

- **Bold highlighting denotes abnormality**

- Abbreviation: Relative Vestibular Reduction (RVR)

- Evaluation of warm caloric and RVR only indicated when asymmetry observed with cool caloric per standard audiology practice.

**eTable 7. Vestibular Impairments Identified Requiring Rehabilitation Interventions**

Case	Static Balance	Dynamic Balance	VOR* Impairment	Unilateral Peripheral Vestibular Impairment
1	X	X	X	
2		X	X	NT
4	X	X		NT
5	X	X	X	
6	X	X	X	NT
8	X	X	X	
9	X	X	X	
10	X	X	X	X
11	X	X	X	X
12	X			NT
13	X	X	X	
15	X	X	X	X
16	X	X	X	
17	X	X	X	
18	X	X	X	
20	X	X	X	X
21	X	X	X	
n	16	16	15	4
(%)	(76)	(76)	(71)	(31)*
+ Vestibulo-ocular reflex (VOR)				
*Percentage is based on 13 individuals who underwent caloric evaluation				
Abbreviations: Not tested (NT)				

**eTable 8.** Standardized Measures Obtained During Initial Neuro-Optometry Evaluation

Case	Self-Reported Measure	Objective Measures			
	CISS*	NPC (cm)		PFV (PD)	DEM (sec)
		Break	Recovery		
1	<b>40</b>	<b>7.5</b>	<b>13</b>	35	29
2	---	2.5	5	25	25
4	---	2.5	5	25	32
5	<b>76</b>	<b>13</b>	<b>20</b>	<b>12</b>	<b>40</b>
6	---	10	15	30	27
9	<b>40</b>	<b>12</b>	<b>23</b>	<b>20</b>	<b>53</b>
10	---	4	7.5	40	27
11	<b>74</b>	<b>7.5</b>	<b>13</b>	<b>16</b>	<b>58</b>
13	<b>51</b>	<b>10</b>	<b>15</b>	<b>18</b>	<b>40</b>
14	---	5	7.5	30	50
15	<b>46</b>	<b>13</b>	<b>25</b>	6	40
16	<b>77</b>	<b>7.5</b>	<b>15</b>	30	74
17	<b>67</b>	<b>25</b>	<b>40</b>	<b>18</b>	<b>67</b>
18	---	5	8	<b>18</b>	<b>38</b>
20	<b>57</b>	<b>7.5</b>	<b>30</b>	6	90

**Normative values**

- Abnormal CISS<sup>27</sup> is  $\geq 16$
- Abnormal NPC<sup>28,29</sup> is  $\geq 6$  cm break and  $\geq 8$  cm for Recovery
- Abnormal PFV<sup>28,29</sup>  $\leq 20$  prism dipters (PD) base out.
- Abnormal DEM<sup>28,30</sup> is  $\geq 30$  seconds
- **Bold highlighting denotes abnormality**

-Abbreviations: Convergence Insufficiency Symptom Survey (CISS); Near Point of Convergence (NPC); Positive Fusional Vergence (PFV); Prism Diopters (PD); Developmental Eye Movement Test (DEM)

\* CISS obtained at initiation of neuro-optometric rehabilitation when indicated per standard neuro-optometry practice.

**eTable 9. Clinically Significant Oculomotor Impairments Identified Requiring Dedicated Neuro-optometric Rehabilitation (n=11)**

Case	Convergence Insufficiency	Accommodative Insufficiency	Saccadic Dysfunction	Pursuit Dysfunction	Photophobia
1	X	*		X	X
5	X	*	X	X	X
6	X			X	X
9	X	*	X		
11	X	X	X	X	X
13	X	*	X	X	X
15	X	*	X	X	X
16	X	X	X	X	X
17	X	*	X	X	X
18	X		X	X	
20	X	*	X	X	X
n	11	2	9	10	9
(%)	(100)	(18)	(82)	(91)	(82)
<p>*Measurements consistent with accommodative insufficiency and historical description of visual change after exposure, however formal diagnosis limited over the age of 40 due to age-appropriate presbyopia.</p> <p>-clinical diagnosis of convergence insufficiency, accommodative insufficiency, saccadic and pursuit dysfunction, and photophobia was performed according to the standards detailed in the methods section, and included integration of standardized measures along with expert clinical evaluation.</p> <p>-of the 4 individuals listed in Table 1 above that did not require formal Neuro-optometric rehabilitation at Penn, one received neuro-optometric rehabilitation after exposure but prior to Penn evaluation, two had oculomotor exercises integrated into vestibular and/or occupational therapy, and was provided a home exercise program.</p>					

**eTable 10.** Pure Tone Audiometry Results

Table 10: Pure Tone Audiometry Results											
		Frequency (Hz)									Hearing Level in dB
Case		250	500	1000	1500	2000	3000	4000	6000	8000	
1	R	10	15	10		15	10	10	15	15	
	L	10	10	10		5	10	10	15	15	
5*	R	15	15	20		20	25	15	5	10	
	L	15	15	20		20	20	15	5	5	
8	R	10	5	5		10	10	5	10	10	
	L	15	10	5		10	15	15	10	5	
9†	R	10	5	5		10	40	45	30	20	
	L	15	5	10		10	55	35	20	10	
10‡	R	5	10	5		15	30	15	5	20	
	L	30	35	40	50	55	55	60	75	95	
11‡	R	15	15	15		10	15	10	15	5	
	L	50	40	35		30	30	25	25	10	
13§	R	15	15	10		10	15	10	25	20	
	L	20	20	15		15	20	25	35	30	
15	R	5	5	15		10	15	20	20	15	
	L	5	15	10		20	15	20	20	20	
16	R	20	20	15		20	15	15	15	20	
	L	10	15	15		15	15	15	15	15	
17§	R	15	20	15		20	25	25	20	15	
	L	20	20	20		10	15	25	20	15	
18	R	5	10	10		5	10	5	10	10	
	L	10	10	5		10	15	10	15	15	
20‡	R	50	45	45	40	25	25	25	25	20	
	L	45	45	40	35	25	25	20	25	20	
21	R	10	15	5		10	5	5	10	10	
	L	15	15	15		10	10	5	10	10	
-Results from Pure Tone Audiometry performed as part of a comprehensive audiological assessment which included Speech Audiometry											
- NOTE: of the 4 cases with sensorineural hearing loss (SNHL) above (9,10, 11, 20), none of the individuals report noticing or being diagnosed with hearing loss prior to exposure. One individual did report frequent ear infections as a child, though reported normal functional hearing until exposure.											
- normal is <=20 dB at each frequency.											
- <b>Bold highlighting denotes abnormality</b>											
* Case 5: isolated impairment with unclear clinical relevance.											
† Case 9: mild to moderate SNHL, no hearing aid indicated.											
‡ Cases 10, 11, and 20: moderate to severe SNHL, received hearing aid.											
§ Cases 13 and 17: borderline to mild SNHL, no hearing aid indicated.											



**eTable 11. Sleep and Headache Medication Requirements**

Case	Impaired Sleep		Headache		Specific Medications Used Included:	
	Subjective Complaint	Medication Required	Subjective Complaint	Medication Required		
1	X	X			Headache Medications N	
2	X		X			
3					Acetaminophen/Aspirin/Caffeine 8 Rizatriptan 5 Sumatriptan 1 Butalbital/Acetaminophen/Caffeine 1 Gabapentin 4 Propranolol 2 Topiramate 1 Amitriptyline 1 Riboflavin 2	
4						
5	X	X	X	X		
6	X	X	X	X		
7	X	X				
8	X	X	X			
9	X	X	X	X		
10	X		X	X		
11	X	X	X	X		
12	X		X	X		
13	X	X	X	X		
14	X	X	X		Sleep Medications N	
15	X	X	X	X		
16	X	X	X	X		
17	X	X	X	X		
18	X	X	X	X		
19					Melatonin 10 Doxepin 6 Gabapentin 6 Trazodone 3	
20	X	X	X	X		
21	X	X	X	X		
n	18	15	16	12	Medications were selected based on clinical indication, efficacy, and tolerance, and were adjusted as clinically indicated. Efforts were made to minimize cognitive side effects	
(%)	(86)	(71)	(76)	(57)		

## eAppendix. Glossary of Terms

**Activities Balance Confidence Scale<sup>19,31</sup> (ABC):** is a widely used self-reported standardized measure which asks a patient to rate their perceived confidence in performing various mobility / movement tasks without a loss of balance or fall. A score of < 67% on this measure indicates that the patient is at risk of falling.

**Balance Error Scoring System<sup>21,22</sup> (BESS):** a standardized test of static balance, which evaluates the ability to maintain stability while performing double limb stance, non-dominant single limb stance, and tandem stance, each on both a firm surface and on foam. Scoring ranges from 0-60, with normative categories (superior, above average, broadly normal, below average, poor, and very poor) based on age and sex.

**Caloric Reflex Testing<sup>24-26</sup>:** Standardized test to evaluate peripheral vestibular end organs, and the clinical gold-standard test identifying a unilateral peripheral vestibulopathy. Interpretation of caloric testing is done by looking at the Relative Vestibular Reduction (RVR) percentage, with an RVR of > 25% asymmetry being diagnostic for a unilateral peripheral vestibular lesion.

**Clinical Test of Sensory Organization and Balance<sup>32,33</sup> (CTSIB):** a non-instrumented, quantitative method of evaluating postural control in different sensory conditions.

**Computerized Dynamic Posturography<sup>23</sup> (CDP):** an instrumented method of quantitating balance functioning. This case series utilized the Sensory Organization Test, a form of CDP, which quantitates the use of visual, proprioceptive, and vestibular cues to maintain postural stability. Given the age group of this case series, a cut off value of 70 for equilibrium score was used to define pathology.

**Convergence Insufficiency Symptom Survey<sup>27</sup> (CISS):** a self-reported measure used to quantify symptoms related to convergence insufficiency and oculomotor dysfunction, and to track symptom

© 2018 American Medical Association. All rights reserved.

improvement throughout neuro-optometric rehabilitation. Abnormal CISS is  $\geq 16$ , and indicates ongoing symptoms related to convergence insufficiency and/or oculomotor dysfunction.

**Developmental Eye Movement Test<sup>28,30</sup> (DEM):** a timed visual-verbal test used to evaluate saccadic eye movement speed and accuracy. Abnormal DEM performance time is  $\geq 30$  seconds, and indicates dysfunction of saccadic eye movements.

**Directional Phenomena:** a term used throughout the manuscript to describe the perception of sound, pressure, and/or vibration emanating from a distinct direction in space.

**Dizziness Handicap Index<sup>18</sup> (DHI):** a standardized measure of perceived impairment related to dizziness, which correlates with vestibular dysfunction: Scoring ranges between mild (0-30), Moderate (31-60), and Severe (61-100) impairment.

**Dynamic Balance:** the ability to maintain postural orientation and postural stability while the body is in motion (ex. walking, running). This is often measured using the Functional Gait Assessment (see below).

**Functional Gait Assessment<sup>20</sup> (FGA):** is a standardized measure used to identify abnormalities in dynamic balance. There are 10 gait conditions (gait with: level surfaces, change gait speed, horizontal head movements, vertical head movements, pivot turns, stepping over an obstacle, narrow base of support (tandem gait), eyes closed, and ambulating backwards) which are each scored from 0 to 3 (0= severe impairment, 1= moderate impairment, 2= mild impairment, 3=normal). Normative score of 30/30.

**Near Point of Convergence<sup>28,29</sup> (NPC):** the closest distance (in cm) at which the patient is no longer able to maintain single vision. It is measured from the brow above the nose and represents the maximum

total convergence response. Target is a small letter on a tongue depressor or a penlight. Normative cut-off is 6 cm.

**Neuropsychological Testing / Battery:**<sup>1-17</sup> A comprehensive assessment of cognitive, neurobehavioral and mood functioning that is performed by a highly trained neuropsychologist. Neuropsychological evaluations typically last for multiple hours, consisting of a thorough clinical interview (e.g., basic demographic information including family, educational and employment history, as well as environmental event details), self-reported symptoms, mood inventories, and extensive objective testing of cognitive domains (e.g., executive functioning, memory, attention, working memory, visual-spatial perception, visual-motor construction, motor functioning, language, reasoning, processing speed, academic functioning).

**Positive Fusional Vergence**<sup>28,29</sup> (PFV) [also known as fusional convergence]: the maximum amount of disparity vergence measured with prisms before a patient reports blur or diplopia. Test distance is 40 cm and normative cut-off is 20 prism diopters base out.

**Static Balance:** the ability to maintain both postural orientation and postural stability while standing still. Static balance is assessed in under multiple conditions, including firm surfaces, unstable surfaces (Ex. foam), both with eyes open and eyes closed.

**Vestibulo-ocular reflex**<sup>25</sup> (VOR): a complex neurologic reflex that coordinates eye and head movements to maintain focus on a visual target.

**Vestibular / Ocular-Motor Screening**<sup>34</sup> (VOMS): standardized measure to quantify symptomatic responses to clinical vestibular and oculomotor testing, specifically evaluation of saccadic eye movements, smooth pursuits, vergence, VOR, and visual motion sensitivity.

© 2018 American Medical Association. All rights reserved.



## eReferences

- 1 Heaton R, Miller S, Taylor M, Grant I. *Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults*. Florida: PAR, 2004.
- 2 Lezak M, Howieson D, Loring D. *Neuropsychological Assessment, Fourth edition*. Oxford, U.K.: Oxford University Press, 2004.
- 3 Strauss E, Sherman E, Spreen O. *A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary third edition*. Oxford, U.K.: Oxford University Press, 2006.
- 4 Tombaugh TN. *Test of memory malingering*. North Tonawanda, NY: Multi-Health Systems, 1996.
- 5 Whitney KA. Predicting test of memory malingering and medical symptom validity test failure within a Veterans Affairs Medical Center: use of the Response Bias Scale and the Henry-Heilbronner Index. *Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists* 2013; **28**: 222-35.
- 6 Jones A. Test of memory malingering: cutoff scores for psychometrically defined malingering groups in a military sample. *The Clinical neuropsychologist* 2013; **27**: 1043-59.
- 7 Bailey KC, Soble JR, O'Rourke JJF. Clinical utility of the Rey 15-Item Test, recognition trial, and error scores for detecting noncredible neuropsychological performance in a mixed clinical sample of veterans. *The Clinical neuropsychologist* 2018; **32**: 119-31.

© 2018 American Medical Association. All rights reserved.



- 8 Love CM, Glassmire DM, Zanolini SJ, Wolf A. Specificity and false positive rates of the Test of Memory Malingering, Rey 15-item Test, and Rey Word Recognition Test among forensic inpatients with intellectual disabilities. *Assessment* 2014; **21**: 618-27.
- 9 Green CM, Kirk JW, Connery AK, Baker DA, Kirkwood MW. The use of the Rey 15-Item Test and recognition trial to evaluate noncredible effort after pediatric mild traumatic brain injury. *Journal of clinical and experimental neuropsychology* 2014; **36**: 261-7.
- 10 Reznek L. The Rey 15-item memory test for malingering: a meta-analysis. *Brain injury* 2005; **19**: 539-43.
- 11 Hays JR, Emmons J, Lawson KA. Psychiatric norms for the Rey 15-item Visual Memory Test. *Percept Mot Skills* 1993; **76**: 1331-4.
- 12 Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *Journal of consulting and clinical psychology* 1988; **56**: 893-7.
- 13 Beck AT, Steer RA. *Beck Anxiety Inventory manual*. San Antonio, TX: Psychological Corporation, 1993.
- 14 Beck AT, Steer RA, Brown GK. *Beck Depression Inventory Manual (2nd ed.)*. San Antonio, TX: The Psychological Corporation, 1996.
- 15 Grace J, Malloy PF. *The Frontal Systems Behavior Scale (FrSBe)*. Odessa, FL: Psychological Assessment Resources, 2002.
- 16 Weathers FW, Huska JA, Keane TM. *PCL-C for DSM-IV*. Boston, MA: National Center for PTSD – Behavioral Science Division, 1991.

- 17 McCutchan PK, Freed MC, Low EC, Belsher BE, Engel CC. Rescaling the Post-Traumatic Stress Disorder Checklist for Use in Primary Care. *Military medicine* 2016; **181**: 1002-6.
- 18 Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. *Archives of otolaryngology--head & neck surgery* 1990; **116**: 424-7.
- 19 Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. *The journals of gerontology. Series A, Biological sciences and medical sciences* 1995; **50A**: M28-34.
- 20 Wrisley DM, Marchetti GF, Kuharsky DK, Whitney SL. Reliability, internal consistency, and validity of data obtained with the functional gait assessment. *Physical therapy* 2004; **84**: 906-18.
- 21 Bell DR, Guskiewicz KM, Clark MA, Padua DA. Systematic review of the balance error scoring system. *Sports health* 2011; **3**: 287-95.
- 22 Iverson GL, Koehle MS. Normative data for the balance error scoring system in adults. *Rehabilitation research and practice* 2013; **2013**: 846418.
- 23 Alahmari KA, Marchetti GF, Sparto PJ, Furman JM, Whitney SL. Estimating postural control with the balance rehabilitation unit: measurement consistency, accuracy, validity, and comparison with dynamic posturography. *Archives of physical medicine and rehabilitation* 2014; **95**: 65-73.

- 24 Barin K. Interpretation and usefulness of caloric testing. In: *Balance Function Assessment and Management* (Jacobson GP, Shepard NT, eds). San Diego, CA: Plural Publishing, 2008: 229–49.
- 25 Ruckenstein MJ, Davis S. Videonystagmography / Electronystagmography. In: *Rapid Interpretation of Balance Function Tests* (Ruckenstein MJ, Davis S, eds). San Diego, CA: Plural Publishing, 2014: 53-83.
- 26 Shepard N, Telian S. *Practical Management of the Balance Disorder Patient*. San Diego, CA: Singular Publishing, 1996.
- 27 Rouse M, Borsting E, Mitchell GL, Cotter SA, Kulp M, Scheiman M, Barnhardt C, Bade A, Yamada T. Validity of the convergence insufficiency symptom survey: a confirmatory study. *Optometry and vision science : official publication of the American Academy of Optometry* 2009; **86**: 357-63.
- 28 Gallaway M, Scheiman M, Mitchell GL. Vision Therapy for Post-Concussion Vision Disorders. *Optometry and vision science : official publication of the American Academy of Optometry* 2017; **94**: 68-73.
- 29 Scheiman M, Wick B. *Clinical Management of Binocular Vision: Heterophoric, Accommodative and Eye Movement Disorders.*, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2014.
- 30 Garzia RP, Richman JE, Nicholson SB, Gaines CS. A new visual-verbal saccade test: the development eye movement test (DEM). *Journal of the American Optometric Association* 1990; **61**: 124-35.

- 31 Lajoie Y, Gallagher SP. Predicting falls within the elderly community: comparison of postural sway, reaction time, the Berg balance scale and the Activities-specific Balance Confidence (ABC) scale for comparing fallers and non-fallers. *Archives of gerontology and geriatrics* 2004; **38**: 11-26.
- 32 Horn LB, Rice T, Stoskus JL, Lambert KH, Dannenbaum E, Scherer MR. Measurement Characteristics and Clinical Utility of the Clinical Test of Sensory Interaction on Balance (CTSIB) and Modified CTSIB in Individuals With Vestibular Dysfunction. *Archives of physical medicine and rehabilitation* 2015; **96**: 1747-8.
- 33 Shumway-Cook A, Horak FB. Assessing the influence of sensory interaction of balance. Suggestion from the field. *Physical therapy* 1986; **66**: 1548-50.
- 34 Mucha A, Collins MW, Elbin RJ, Furman JM, Troutman-Enseki C, DeWolf RM, Marchetti G, Kontos AP. A Brief Vestibular/Ocular Motor Screening (VOMS) assessment to evaluate concussions: preliminary findings. *The American journal of sports medicine* 2014; **42**: 2479-86.



# Neurological Manifestations Among US Government Personnel Reporting Directional Audible and Sensory Phenomena in Havana, Cuba

Randel L. Swanson II, DO, PhD; Stephen Hampton, MD; Judith Green-McKenzie, MD, MPH; Ramon Diaz-Arrastia, MD, PhD; M. Sean Grady, MD; Ragini Verma, PhD; Rosette Biester, PhD; Diana Duda, PT, DPT; Ronald L. Wolf, MD, PhD; Douglas H. Smith, MD

**IMPORTANCE** From late 2016 through August 2017, US government personnel serving on diplomatic assignment in Havana, Cuba, reported neurological symptoms associated with exposure to auditory and sensory phenomena.

**OBJECTIVE** To describe the neurological manifestations that followed exposure to an unknown energy source associated with auditory and sensory phenomena.

**DESIGN, SETTING, AND PARTICIPANTS** Preliminary results from a retrospective case series of US government personnel in Havana, Cuba. Following reported exposure to auditory and sensory phenomena in their homes or hotel rooms, the individuals reported a similar constellation of neurological symptoms resembling brain injury. These individuals were referred to an academic brain injury center for multidisciplinary evaluation and treatment.





**EXPOSURES** Report of experiencing audible and sensory phenomena emanating from a distinct direction (directional phenomena) associated with an undetermined source, while serving on US government assignments in Havana, Cuba, since 2016.

**MAIN OUTCOMES AND MEASURES** Descriptions of the exposures and symptoms were obtained from medical record review of multidisciplinary clinical interviews and examinations. Additional objective assessments included clinical tests of vestibular (dynamic and static balance, vestibulo-ocular reflex testing, caloric testing), oculomotor (measurement of convergence, saccadic, and smooth pursuit eye movements), cognitive (comprehensive neuropsychological battery), and audiometric (pure tone and speech audiometry) functioning. Neuroimaging was also obtained.

**RESULTS** Of 24 individuals with suspected exposure identified by the US Department of State, 21 completed multidisciplinary evaluation an average of 203 days after exposure. Persistent symptoms (>3 months after exposure) were reported by these individuals including cognitive (n = 17, 81%), balance (n = 15, 71%), visual (n = 18, 86%), and auditory (n = 15, 68%) dysfunction, sleep impairment (n = 18, 86%), and headaches (n = 16, 76%). Objective findings included cognitive (n = 16, 76%), vestibular (n = 17, 81%), and oculomotor (n = 15, 71%) abnormalities. Moderate to severe sensorineural hearing loss was identified in 3 individuals. Pharmacologic intervention was required for persistent sleep dysfunction (n = 15, 71%) and headache (n = 12, 57%). Fourteen individuals (67%) were held from work at the time of multidisciplinary evaluation. Of those, 7 began graduated return to work with restrictions in place, home exercise programs, and higher-level work-focused cognitive rehabilitation.

**CONCLUSIONS AND RELEVANCE** In this preliminary report of a retrospective case series, persistent cognitive, vestibular, and oculomotor dysfunction, as well as sleep impairment and headaches, were observed among US government personnel in Havana, Cuba, associated with reports of directional audible and/or sensory phenomena of unclear origin. These individuals appeared to have sustained injury to widespread brain networks without an associated history of head trauma.

JAMA. 2018;319(11):1125-1133. doi:10.1001/jama.2018.1742  
Published online February 15, 2018.

-  Editorial page 1098
-  Author Audio Interview
-  Related article page 1079
-  Supplemental content

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Douglas H. Smith, MD, Department of Neurosurgery and Center for Brain Injury and Repair, University of Pennsylvania, Perelman School of Medicine, 3320 Smith Walk, 105 Hayden Hall, Philadelphia, PA 19104 (smithdou@upenn.edu).



In late 2016, US government personnel serving in Havana, Cuba, began presenting to their embassy medical unit after experiencing unusual auditory and/or sensory stimuli of variable intensity and character, with associated onset of varied neurological manifestations. Initial signs and symptoms pointed toward injury of the auditory system, leading to the establishment of a triage program at the University of Miami centered around otolaryngology evaluation. Eighty embassy community members underwent initial evaluation between February and April 2017, and 16 individuals were identified with similar exposure history and a constellation of neurological signs and symptoms commonly seen following mild traumatic brain injury, also referred to as concussion.<sup>1</sup> Exposures continued with time and 8 additional individuals were identified who had similar findings. The US Department of State, Bureau of Medical Services, subsequently convened an expert panel in July 2017, which came to consensus that the triage findings were most likely related to neurotrauma from a nonnatural source and recommended that further investigation into this novel cluster of findings was necessary.

The University of Pennsylvania's Center for Brain Injury and Repair was subsequently selected to coordinate multidisciplinary clinical evaluation, treatment, and rehabilitation of individuals identified during initial triage and additional patients with exposure. The purpose of this preliminary communication is to describe preliminary findings from 21 patients who were exposed to the same nonnatural source.<sup>1</sup>

## Methods

### Design

This retrospective study was approved by the institutional review board of the University of Pennsylvania's Perelman School of Medicine, which waived the need for informed consent. The participants signed general consent forms for treatment permitting use of their data in research. Because of security and confidentiality considerations, individual-level demographic data cannot be reported.

### Clinical Approach

The US Department of State directly referred individuals with suspected exposure to the University of Pennsylvania for comprehensive evaluation and treatment. A multidisciplinary team was convened consisting of physical medicine and rehabilitation, occupational medicine, neurology, neuroradiology, and neurosurgery. Each specialist independently obtained clinical histories and conducted comprehensive assessments. Reported signs and symptoms were extracted from these interviews.

Based on individual clinical indication, additional referrals were made to vestibular physical therapy, neuro-optometry, neuropsychology, occupational therapy, speech therapy, audiology, otorhinolaryngology, and sleep medicine for focused evaluation and treatment. Patients were referred to the University of Pennsylvania for clinical care, as opposed to enrollment in a structured research study. The Box shows

### Key Points

**Question** Are there neurological manifestations associated with reports of audible and sensory phenomena among US government personnel in Havana, Cuba?

**Findings** In this case series of 21 individuals exposed to directional audible and sensory phenomena, a constellation of acute and persistent signs and symptoms were identified, in the absence of an associated history of blunt head trauma. Following exposure, patients experienced cognitive, vestibular, and oculomotor dysfunction, along with auditory symptoms, sleep abnormalities, and headache.

**Meaning** The unique circumstances of these patients and the consistency of the clinical manifestations raised concern for a novel mechanism of a possible acquired brain injury from a directional exposure of undetermined etiology.

an abbreviated list of objective measures used during clinical assessments and supplements for additional information.<sup>2-29</sup>

### Cognitive, Neurobehavioral, and Mood Evaluations

When clinically indicated, comprehensive neuropsychological assessments were conducted by experienced neuropsychologists, who were not blinded to patient status. Neuropsychological test batteries included assessment of the following domains: (1) auditory attention; (2) auditory and visual working memory; (3) auditory and visual memory; (4) visual-spatial perception; (5) visual-motor construction; (6) motor function; (7) language function; (8) executive function; (9) processing speed; (10) academic achievement; (11) reasoning; (12) mood functioning; and (13) effort (Box and Appendix in the Supplement). Following neuropsychological testing, individuals with cognitive deficits were referred for cognitive rehabilitation with occupational therapy, speech therapy, or both, depending on the individual clinical indication. Cognitive rehabilitation was intentionally not started prior to completion of neuropsychological testing to avoid affecting results.

### Balance and Vestibular Evaluations

Clinical evaluations identifying balance abnormalities prompted referral to vestibular physical therapy. Focused vestibular evaluation included expert clinical assessment and the use of validated measures of static and dynamic balance (Box).<sup>15-21</sup> Also per clinical indications, patients were referred to audiology for comprehensive evaluation of the peripheral vestibular system, including caloric reflex testing.<sup>23,24</sup> Individuals confirmed to have a unilateral peripheral vestibulopathy (ie, relative vestibular reduction of  $\geq 25\%$  on caloric reflex testing) underwent magnetic resonance imaging (MRI) of the head with and without gadolinium contrast, with focus on the internal auditory canals in addition to the MRI sequences detailed.

### Oculomotor Evaluations

Individuals found on clinical evaluation to have abnormalities of oculomotor function were referred to neuro-optometry for further evaluation and treatment. Oculomotor function was



quantified using the following standard optometric clinical measures (Box).<sup>25,26</sup> Vergence testing included step vergence with prism bar, vergence facility with prisms, and near point of convergence. Accommodative testing in nonpresbyopic patients included amplitude of accommodation, accommodative facility with plus and minus lenses, and accommodative lag. Pursuit and saccadic testing was done qualitatively to assess accuracy of tracking eye movements and whether symptoms were provoked as with Vestibular/Ocular Motor Screening.<sup>29</sup> Saccadic speed and accuracy were quantified using the Developmental Eye Movement test,<sup>26,28</sup> a timed visual-verbal test. Diagnoses of accommodative, vergence, and/or saccadic/pursuit dysfunction were made using standardized criteria, in conjunction with symptomatic reporting,<sup>26</sup> which were quantified using the Convergence Insufficiency Symptoms Survey.<sup>27</sup>

#### Auditory Evaluations

Audiometry evaluations were performed prior to referral for care at the University of Pennsylvania. However, when patients had balance function testing as described here, comprehensive audiology evaluation included both pure tone and speech audiometry.

#### Imaging Evaluations

Initial conventional MRI sequences were acquired at 3T on a Siemens Magnetom Prisma<sup>31</sup> scanner, and included high-resolution sagittal 3-dimensional MP-RAGE, T2 SPACE and FLAIR SPACE, coronal 2-dimensional T2-weighted imaging, axial 2-dimensional diffusion-weighted imaging, and axial T2\* gradient echo. Resulting images were clinically interpreted by neuroradiology clinicians.

### Results

There were 21 individuals evaluated (11 women and 10 men, with a mean age of 43 years). Multidisciplinary evaluations began an average of 203 days (range, 3-331 days; median, 189 days; interquartile range, 125 days) following exposure (Table 1).

#### Exposure

For 18 of the 21 individuals (86%), there were reports of hearing a novel, localized sound at the onset of symptoms in their homes and hotel rooms (Table 2). Affected individuals described the sounds as directional, intensely loud, and with pure and sustained tonality. Of the patients, high-pitched sound was reported by 16 (76%), although 2 (10%) noted a low-pitched sound. Words used to describe the sound include "buzzing," "grinding metal," "piercing squeals," and "humming."

The sounds were often associated with pressurelike ( $n = 9$ ; 43%) or vibratory ( $n = 3$ ; 14%) sensory stimuli, which were also experienced by 2 of the 3 patients who did not hear a sound. The sensory stimuli were likened to air "baffling" inside a moving car with the windows partially rolled down.

Both the sound and sensory stimuli were often described as directional in that the individuals perceived a distinct direction from which the sensation emanated (hereafter re-

#### Box: Examples of Standardized Measures Used in Clinical Assessments<sup>a</sup>

##### Cognitive

Boston Diagnostic Aphasia Examination<sup>2</sup>  
California Verbal Learning Test-2nd Edition<sup>3</sup>  
Grooved Pegboard<sup>4</sup>  
Test of Memory Malingering<sup>5</sup>  
Trail Making Test, Parts A and B<sup>6</sup>  
Wechsler Adult Intelligence Scale-IV<sup>7</sup>  
Wechsler Memory Scale-IV<sup>8</sup>

##### Mood

Beck Depression Inventory (2nd edition)<sup>9</sup>  
Beck Anxiety Inventory<sup>10,11</sup>  
Frontal Systems Behavior Scale<sup>12</sup>  
Post-Traumatic Stress Disorder Checklist<sup>13,14</sup>

##### Balance and vestibular

Functional Gait Assessment<sup>15</sup>  
Activities-Specific Balance Confidence<sup>16</sup>  
Balance Error-Scoring System<sup>17</sup>  
Clinical Test of Sensory Organization and Balance<sup>18,19</sup>  
Dizziness Handicap Index<sup>20</sup>  
Computerized Dynamic Posturography<sup>21,22</sup>  
Caloric reflex test<sup>23,24</sup>

##### Vision and oculomotor

Formal Evaluation of Vergence and Accommodation<sup>25,26</sup>  
Convergence Insufficiency Symptoms Survey<sup>27</sup>  
Developmental Eye Movement Test<sup>26,28</sup>  
Vestibular/Ocular Motor Screening<sup>29</sup>

<sup>a</sup> Measures were used based on clinical indications; therefore, every patient did not complete all measures in this abbreviated list.

ferred to as *directional phenomena*). Further, the directional phenomena appeared to be localized to a precise area, as individuals ( $n = 12$ , 57%) noted that after changing location, the sensation disappeared and the associated symptoms reduced. Five individuals (24%) reported covering their head and/or ears, although doing so did not result in attenuation of the directional phenomena.

Accurately determining the dose and duration of exposure has been difficult because of the limitations of patient recall. Some patients were awakened by sounds and were unsure of the start of the event. The shortest reported event involved two 10-second pulses reported as a single exposure episode, whereas other patients reported that they perceived sound continuously for longer than 30 minutes. Owing to security concerns, further details of potential dosage cannot be provided.

Of the affected individuals, 20 (95%) reported immediate onset of neurological symptoms associated with directional phenomena (eTable 1 in the Supplement). One individual awoke from sleep with acute symptoms (including headache, unilateral ear pain, and hearing changes) but did not perceive directional phenomena. From days to weeks after exposure, individuals reported that they experienced the onset

Table 1. Demographics of Patients Evaluated at the University of Pennsylvania<sup>a</sup>

	Men (n = 10)	Women (n = 11)	Total (N = 21)
Age, mean (SD), y	39 (7)	47 (8)	43 (8)
Time from exposure to evaluation, mean (SD), d	229 (98)	180 (85)	203 (93)

<sup>a</sup> Potentially identifying information intentionally omitted for security and privacy concerns.

Table 2. Exposure Descriptions of the Directional Phenomena

Patient No.	Associated Sound			Associated Sensory Stimuli				Duration >3 mo		
	Reported	High Pitch	Low Pitch	Reported	Pressure	Vibration	Movement Attenuation <sup>b</sup>	Persistent Symptoms	Objective Findings	Required Treatment
1	X	X					X	X	X	X
2	X	X					X	X	X	X
3	X	X					X			
4	X		X	X		X		X	X	X
5	X	X		X	X			X	X	X
6	X		X	X	X		X	X	X	X
7				X	X		X	X		
8	X	X					X	X	X	X
9	X	X		X		X		X	X	X
10	X	X		X		X		X	X	X
11	X	X		X	X			X	X	X
12	X	X		X	X			X	X	X
13	X	X					X	X	X	X
14	X	X					X	X	X	X
15	X	X		X	X		X	X	X	X
16	X	X					X	X	X	X
17	X	X		X	X		X	X	X	X
18								X	X	X
19	X	X		X	X			X		
20				X	X		X	X	X	X
21	X	X						X	X	X
No. (%)	18 (86)	16 (76)	2 (10)	12 (57)	9 (43)	3 (14)	12 (57)	20 (95)	18 (86)	18 (86)

<sup>b</sup> Patients reported attenuation of sound, pressure, or vibration when moving to a different location.

of additional cognitive, neurobehavioral/mood, and physical symptoms. Twenty individuals (95%) reported that they experienced persistent (>3 months) symptoms, and 18 individuals (86%) exhibited objective clinical manifestations in 6 predominant domains (Table 3).

#### Cognitive, Neurobehavioral, and Mood Findings

Persistent cognitive manifestations were reported by 17 individuals (81%). Subjective symptoms included memory problems (n = 16, 76%), feeling mentally foggy (n = 16, 76%), impaired concentration (n = 15, 71%), and feeling cognitively slowed (n = 14, 67%) (Table 3). In addition, they reported neurobehavioral difficulties including irritability (n = 14, 67%), nervousness (n = 12, 57%), feeling more emotional (n = 11, 52%), and sadness (n = 5, 24%). For at least 6 individuals (29%), a clear change in work performance was noted by supervisors and colleagues (eTable 1 in the Supplement). Individuals also reported a "good day-bad day" pattern where significant cognitive or physical exertion would be followed by exacerbation of their symptoms for several days. Cognitive symptoms, as well as disequilibrium and headache, reportedly were also frequently exacerbated by cardiovascular exercise.

Multidisciplinary evaluations raised concern for cognitive impairment in 16 individuals (76%). Prior to referral, 4 of these individuals underwent neuropsychological evaluation (data not shown as generated outside of the University of Pennsylvania). Repetition of comprehensive neuropsychological testing is precluded within 1 year due to practice effects when material is presented within this timeframe. With previous exposure to material, the individual may score higher on a repeated neuropsychological evaluation within 1 year. Neuropsychological assessments were performed on 10 individuals after referral. Of those, interpretation was ongoing in 4 at the time of this publication. Per their preference, 2 individuals did not complete neuropsychological testing.

For the 6 individuals with complete neuropsychological testing data and analysis at the University of Pennsylvania, all had significant areas of cognitive weakness and/or impairment (eTables 2, 3, and 4 in the Supplement). Impairments were found in executive function (n = 6), motor function (n = 5), auditory and visual memory (n = 4), visual-spatial perception and visual-motor construction (n = 4), auditory attention and working memory (n = 3), language (n = 3), processing speed (n = 4), and reasoning (n = 1). All individuals



Table 3. Prevalence of Persistent Symptoms and Objective Findings<sup>a</sup>

Domain	Subjective		Objective	
	Symptom	No. (%)	Finding	No. (%)
Cognitive and behavioral	Combined	17 (81)	Neuropsychological testing indicated	16 (76) <sup>b</sup>
	Difficulty remembering	16 (76)	Neuropsychological testing performed at Penn	10 (48)
	Mental fog	16 (76)	Neuropsychological testing outside Penn	4 (19)
	Difficulty concentrating	15 (71)	Neuropsychological testing not yet performed	2 (10)
	Feeling slowed	14 (67)	Cognitive rehabilitation	13 (62) <sup>c</sup>
	Irritability	14 (67)		
	Feeling more emotional	11 (52)		
Balance and vestibular	Combined	15 (71)	Vestibular physical therapy referral	17 (81)
	Balance problems	14 (67)	Static postural stability	16 (76)
	Dizziness	13 (62)	Dynamic balance	16 (76)
	Nausea	7 (33)	VOR dysfunction	15 (71)
			Unilateral caloric impairment	4 (31) <sup>c</sup>
Vision and oculomotor	Combined	18 (86)	Vestibular rehabilitation	17 (81)
	Visual problems	16 (76)	Neuro-optometry referral	15 (71)
	Light sensitivity	13 (62)	Convergence insufficiency	11 (52)
	Difficulty reading	12 (57)	Smooth pursuit dysfunction	11 (52)
	Eye strain	11 (52)	Saccadic dysfunction	10 (47)
			Neuro-optometric rehabilitation	14 (67)
Auditory	Combined	15 (68)	Audiology referral	13 (62)
	Sound sensitivity	14 (67)	Moderate to severe SNHL	3 (23) <sup>c</sup>
	Tinnitus	12 (57)	Hearing aid provided	3 (14)
	Hearing reduction	9 (43)		
	Ear pressure	8 (38)		
Sleep	Combined	18 (86)	Pharmacological intervention	15 (71)
	Drowsiness or fatigue	16 (76)		
	Decreased sleep duration	15 (71)		
	Trouble falling asleep	14 (67)		
Headache	Combined	16 (76)	Pharmacological intervention	12 (57)
	With cognitive tasks	13 (62)		
	With therapy	11 (52)		
	Due to photophobia	9 (43)		
	Due to phonophobia	6 (29)		
Overall	Combined subjective	20 (95)	Combined objective	18 (86)

Abbreviations: Penn, University of Pennsylvania; SNHL, sensorineural hearing loss; VOR, vestibulo-ocular reflex.

<sup>a</sup> Persistent defined as presence more than 3 months after exposure.

<sup>b</sup> Neuropsychological characterization ongoing. Start of cognitive rehabilitation held until neuropsychological testing performed.

<sup>c</sup> Of 13 patients tested thus far during persistent symptom evaluation.

demonstrated a high level of effort during testing and had intact cognitive domains including visual working memory and academic achievement.

Neurobehavioral function was evaluated using the Frontal System Behavior Scale, a self-report measure of frontal lobe dysfunction. Specifically, comparing before and after exposure retrospectively via patient recall and self-report, individuals noted apathy ( $n = 5$ ), executive dysfunction ( $n = 4$ ), and disinhibition ( $n = 2$ ). Two individuals met criteria for post-traumatic stress disorder and endorsed severe levels of anger on the Brief Mood Survey, 1 of whom also endorsed moderate to severe levels of depression and anxiety.

#### Balance and Vestibular Findings

Individuals described acute nausea ( $n = 7$ , 33%) and dizziness ( $n = 5$ , 24%) during exposure, which continued to progress

in the subacute and persistent stages (acute stage = during or hours following exposure; subacute stage = days to weeks after exposure patient recall); and persistent stage = more than 3 months after exposure). Specifically, more than 3 months after exposure, individuals reported a higher prevalence of dizziness ( $n = 13$ , 62%) and nausea ( $n = 7$ , 33%), in addition to general balance problems ( $n = 14$ , 67%) (Table 3). These symptoms were exacerbated by walking quickly, tasks involving head movements, complex visual environments, or in some cases while simply standing still. Balance symptoms were also worsened with eyes closed or in low light conditions.

Clinical examinations raised concern for balance impairment in 17 patients (81%), prompting referral to vestibular physical therapy. Focused vestibular evaluations demonstrated impairments in static postural stability ( $n = 16$ , 76%), dynamic



balance ( $n = 16$ , 76%), and the vestibulo-ocular reflex ( $n = 15$ , 71%) (eTables 5, 6, and 7 in the Supplement). Patients with the most severe balance impairments on clinical evaluation underwent caloric reflex testing, which demonstrated peripheral vestibular dysfunction in 4 of 13 patients evaluated. MRI findings focusing on the internal auditory canals on these 4 patients were normal. Taken together, these balance symptoms and evaluation findings are consistent with central and, in some cases, peripheral vestibular abnormalities.

#### Oculomotor Findings

Of the individuals with persistent symptoms, 16 (76%) reported visual problems (Table 3). Light sensitivity ( $n = 13$ , 62%) and difficulty reading ( $n = 12$ , 57%) were also frequently reported. Eye strain ( $n = 11$ , 52%) was experienced particularly with reading and was associated with headaches, disequilibrium, and nausea.

Clinical examinations raised concern for oculomotor dysfunction in 15 individuals (71%), prompting referral to neuro-optometry. The most common findings confirmed on focused oculomotor evaluation were convergence insufficiency ( $n = 11$ , 52%), abnormal smooth pursuits ( $n = 11$ , 52%), and saccadic dysfunction ( $n = 10$ , 47%) (eTables 8 and 9 in the Supplement). Similar to vestibular testing that provoked symptoms, oculomotor examination elicited headache and disequilibrium.

#### Auditory Findings

At the onset of the directional phenomena, affected individuals reported hearing a loud sound ( $n = 18$ , 86%), associated with ear pain ( $n = 7$ , 33%) and tinnitus ( $n = 6$ , 29%). Within days to weeks following exposure, individuals continued to report tinnitus ( $n = 12$ , 57%) and ear pain ( $n = 5$ , 24%), with the addition of a change in hearing ( $n = 7$ , 33%) and sensitivity to noise ( $n = 5$ , 24%). More than 3 months after exposure, sound sensitivity was the most common auditory concern ( $n = 14$ , 67%), followed by tinnitus ( $n = 12$ , 57%) and ear pressure ( $n = 8$ , 38%).

While 9 individuals (43%) reported persistent hearing reduction, pure tone audiometry, including pure tone average and word identification, revealed moderate to severe sensorineural hearing loss in 3 individuals (23%) (eTable 10 in the Supplement), who were fitted with hearing aids. For 2 individuals, the moderate to severe sensorineural hearing loss was unilateral and corresponded with the side of peripheral vestibular dysfunction on caloric testing. Otoscopy and tympanometry findings were unremarkable.

#### Sleep

Individuals commonly reported issues with sleep ( $n = 18$ , 86%), including reduced sleep duration ( $n = 15$ , 71%) and difficulty falling asleep ( $n = 14$ , 67%). In addition, individuals experienced significant daytime fatigue ( $n = 16$ , 76%). Most individuals required pharmacological intervention to improve subjective report of sleep architecture ( $n = 15$ , 71%) (eTable 11 in the Supplement).

#### Headaches

At the initiation of directional phenomena exposure, 8 individuals (38%) reported immediate onset of headache, while 5

(24%) reported intense head pressure. In the days to weeks following exposure, 17 individuals (81%) developed headaches, with 16 (76%) experiencing persistent headaches longer than 3 months after exposure (Table 3).

In the persistent stage, headaches were reported to be exacerbated or associated with cognitive tasks ( $n = 13$ , 62%), rehabilitative therapies ( $n = 11$ , 52%), photophobia ( $n = 9$ , 43%), and phonophobia ( $n = 6$ , 29%). Patients with antecedent headaches were able to differentiate the character of these headaches from that of their standard headaches. Headaches were generally reported to improve with medications ( $n = 12$ , 57%) and appropriate therapies for oculomotor and vestibular impairments (eTable 11 in the Supplement).

#### Imaging

MRI neuroimaging was obtained in all 21 patients. Most patients had conventional imaging findings, which were within normal limits, at most showing a few small nonspecific T2-bright foci in the white matter ( $n = 9$ , 43%). There were 3 patients with multiple T2-bright white matter foci, which were more than expected for age, 2 mild in degree, and 1 with moderate changes. The pattern of conventional imaging findings in these cases was nonspecific with regard to the exposure/insult experienced, and the findings could perhaps be attributed to other preexisting disease processes or risk factors. Advanced structural and functional neuroimaging studies are ongoing.

#### Rehabilitation and Return to Work

Individualized rehabilitation programs were developed, which included combinations of neuro-optometric rehabilitation ( $n = 14$ , 67%), vestibular physical therapy ( $n = 17$ , 81%), and cognitive rehabilitation with speech pathology and/or occupational therapy ( $n = 13$ , 62%). The most symptomatic patients ( $n = 14$ , 67%) requiring multiple therapies did not return to work.

Vestibular physical therapy sessions focused on balance retraining, static and dynamic posture control with substitution via visual and somatosensory systems, gaze stabilization exercises, habituation, smooth pursuits, and saccadic eye movement exercises. Patients treated with vestibular rehabilitation have demonstrated a positive response with improved balance and reduction of disequilibrium.

Formal neuro-optometric rehabilitation, including manipulation of disparity vergence and accommodative amplitude and latency, has been used to treat ocular motor deficits. Rehabilitation for abnormal smooth pursuit and saccadic dysfunction was coordinated between neuro-optometric rehabilitation, vestibular physical therapy, and occupational therapy. Vestibular physical therapy focused on oculomotor function with the body in motion and occupational therapy emphasized functional tasks such as visual scanning in a simulated work environment.

Following comprehensive neuropsychological testing, a formal cognitive rehabilitation program was initiated in the form of occupational therapy and/or speech therapy.

Early return to work with intensive cognitive loading led to an exacerbation of neurocognitive, vestibular, and visual



symptoms in 7 individuals (33%). Individualized return to work plans were designed to reintegrate individuals using a stepwise process and appropriate work modifications.

## Discussion

Preliminary findings are described of a case series of individuals stationed in Havana, Cuba, nearly all of whom reported directional audible and/or sensory phenomena that was followed by the development of a consistent cluster of neurological signs and symptoms. The clinical manifestations may represent a novel clinical entity, which appears to have resulted from a widespread brain network dysfunction (ie, cognitive, oculomotor, and central vestibular) as seen in mild traumatic brain injury, or concussion,<sup>30</sup> as well as injury to the peripheral vestibular system in some cases. It is currently unclear if or how the noise is related to the reported symptoms. In particular, sound in the audible range (20 Hz–20 000 Hz) is not known to cause persistent injury to the central nervous system and therefore the described sounds may have been associated with another form of exposure.

Cognitive symptoms, including difficulty remembering ( $n=16$ , 76%) and feeling cognitively slowed ( $n=14$ , 67%) were the most problematic for individuals in this series more than 3 months after exposure, with neuropsychological testing identifying impairments in at least 1 cognitive domain in all 6 patients who completed neuropsychological evaluation to date (eTables 2, 3, and 4 in the Supplement). Cognitive difficulties interfered with these patients' ability to multitask, process information quickly with accurate recall, solve problems, and perform rapid decision making. Compared with vestibular and oculomotor impairments, cognitive impairments are often the slowest to improve following acquired brain injury, which was observed in this series. Therefore, extended cognitive rehabilitation with emphasis on return to work was used. In addition, it is not uncommon for patients with neurological injury resulting in cognitive impairment to have mood disturbances such as depression, anxiety, and/or posttraumatic stress disorder. Mood dysfunction can directly result from acquired brain injury or develop in response to the precipitating event and novel deficits.<sup>31–33</sup>

The presence of subjective neurological symptoms presenting in a cohesive community has raised concerns for collective delusional disorders, including mass psychogenic illness. However, neurological examination and cognitive screens did not reveal evidence of malingering, and objective testing and behavioral observations during cognitive testing indicated high levels of effort and motivation. Several of the objective manifestations consistently found in this cohort (such as oculomotor and vestibular testing abnormalities) could not have been consciously or unconsciously manipulated. Furthermore, mass psychogenic illness is often associated with transient, benign symptoms with rapid onset and recovery often beginning with older individuals.<sup>34,35</sup> In contrast, the Havana cohort experienced persisting disability of a significant nature and are broadly distributed in age. Rather than seeking time away from the workplace, the patients

were largely determined to continue to work or return to full duty, even when encouraged by health care professionals to take sick leave.

While not systematically excluded, viral etiologies, chemical etiologies, or both associated with acute onset of persistent neurological impairment and peripheral vestibulopathy with the directional nature of exposure descriptions are not readily apparent. No other manifestations of viral illness, such as preceding fever, were identified. It is unlikely a chemical agent could produce these neurological manifestations in the absence of other organ involvement, particularly given that some individuals developed symptoms within 24 hours of arriving in Havana.

There are important considerations in this investigation. In particular, the anatomic substrates causing the symptoms have not yet been identified. This may represent a significant challenge because even the designation of "concussion," is not yet a true diagnosis, as no definitions include the underlying cause. Nonetheless, there is an emerging consensus that concussion, or mild traumatic brain injury, is a type of brain network disorder, based on classic symptoms (eg, slowed processing speed and memory dysfunction) as well as changes in the white matter tracts and consecutive connectivity, as detected with advanced neuroimaging studies.<sup>30,36</sup>

Beyond the absence of blunt head trauma, there were additional notable differences between the manifestations observed in the Havana cohort and characteristic acute and persistent symptoms of concussion. For example, individuals experienced unilateral ear pain and tinnitus after exposure, and some were later detected to have a unilateral peripheral vestibulopathy (along with central vestibular dysfunction), a finding uncommon in concussion. Further, studies have reported that while most individuals following concussion have a relatively rapid full recovery, at least 15% are thought to experience characteristic persisting symptoms.<sup>37,38</sup> In contrast to classic concussions, most patients referred following suspected exposure in Havana exhibited significant impairment that persisted for months with no significant improvement in multiple cases until rehabilitation was initiated.

For practicing clinicians, if a patient presents reporting a similar potential exposure and symptoms similar to those observed in mild traumatic brain injury, in addition to a thorough history, objective evaluation should include screening assessments of vestibular, oculomotor, and cognitive functioning. Based on findings of this assessment, appropriate referrals to subspecialists should be considered including neurorehabilitation psychiatry, vestibular physical therapy, neuro-optometry, neuropsychology, and audiology.

## Limitations

This study has several limitations. First, due to the sensitive nature of this publication, certain details typically reported in a case series of exposure were omitted, including specifics about geography, relationships between individuals, and individual demographics. Second, because these patients' first evaluation was elsewhere, each patient did not undergo each of the tests described. In particular, neuropsychological characterization was incomplete at the time of publication.



Preliminary results were presented given the importance and strong public interest in this case series. Third, the rehabilitative course of this Havana cohort may not be representative because this represents a referral population. There may be additional individuals exposed while in Havana, Cuba, who have not been identified due to subtler manifestations that either resolved spontaneously or did not prompt presentation for medical treatment. Therefore, the actual number of individuals exposed is unknown, and the relative "dose" of exposure that causes acute and chronic symptoms remains unclear.

## Conclusions

In this preliminary report of a retrospective case series, persistent cognitive, vestibular, and oculomotor dysfunction, as well as sleep impairment and headaches, were observed among US government personnel in Havana, Cuba, associated with reports of directional audible and/or sensory phenomena of unclear origin. These individuals appeared to have sustained injury to widespread brain networks without an associated history of head trauma.

## ARTICLE INFORMATION

Accepted for Publication: February 8, 2018

Published Online: February 15, 2018.

doi:10.1001/jama.2018.1742

**Author Affiliations:** Department of Physical Medicine and Rehabilitation, University of Pennsylvania, Perelman School of Medicine, Philadelphia (Swanson, Hampton, Biester); Center for Brain Injury and Repair, University of Pennsylvania, Philadelphia (Swanson, Hampton, Green-McKenzie, Diaz-Arastia, Grady, Verma, Biester, Duda, Wolf, Smith); Division of Occupational and Environmental Medicine, Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Green-McKenzie); Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia (Diaz-Arastia); Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia (Grady, Smith); Department of Radiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia (Verma, Wolf); Penn Therapy & Fitness, Good Shepherd Penn Partners, University of Pennsylvania, Philadelphia (Duda).

**Author Contributions:** Drs Smith and Swanson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Swanson, Hampton, Smith. **Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Swanson, Hampton, Biester, Duda, Smith.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Swanson, Hampton, Smith. **Administrative, technical, or material support:** All authors.

**Supervision:** Swanson, Smith.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Dr Green-McKenzie reported receiving grants from Health Resources and Services Administration and the National Institute for Occupational Safety and Health. No other disclosures were reported.

**Disclaimer:** Support for this article was provided by the US government in the form of background information and referral of patients. The findings and conclusions are those of the authors and should not be construed as officially reflecting the views of the US Department of State.

**Additional Contributions:** We are grateful to the following individuals, who did not receive compensation for their role in the study: Michael Gallaway, OD (neuro-optometry consultant; Department of Optometry, Salus University, Philadelphia); Mary-Fran Madden, OTR/L, CBIS, MSCS (occupational therapy consultant; Penn Therapy & Fitness, Good Shepherd Penn Partners, University of Pennsylvania, Philadelphia); Darlene Mancini, CCC-SLP (speech language pathology consultant; Penn Therapy & Fitness, Good Shepherd Penn Partners, University of Pennsylvania, Philadelphia); Danielle Sandsmark, MD, PhD (neurology consultant; Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia); Grant Liu, MD (neuro-ophthalmology; Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia); Nora Johnson, MBA, MS, PsyD (neuropsychology consultant; Department of Physical Medicine & Rehabilitation, University of Pennsylvania, Perelman School of Medicine, Philadelphia); Sherrie Davis, AuD (audiology consultant; Department of Otorhinolaryngology, University of Pennsylvania, Perelman School of Medicine, Philadelphia); Michael J. Ruckenstein, MD (otorhinolaryngology consultant; Department of Otorhinolaryngology, University of Pennsylvania, Perelman School of Medicine, Philadelphia); Charles Bae, MD (sleep medicine consultant; Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia); David M. Razen, MD, PhD (sleep medicine consultant, Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia); Sharon Schutte-Rodin, MD (sleep medicine consultant; Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia); and Douglas J. Wiebe, PhD (epidemiology and biostatistics consultant; Department of Biostatistics and Epidemiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia).

## REFERENCES

1. US Senate Committee on Foreign Relations. Subcommittee on Western Hemisphere, Transnational Crime, Civilian Security, Democracy, Human Rights, and Global Women's Issues. Attacks on US diplomats in Cuba. <https://www.foreign.senate.gov/hearings/attacks-on-us-diplomats-in-cuba-response-and-oversight-010918>. Published January 9, 2018. Accessed February 8, 2018.
2. Goodglass H, Kaplan E, Barresi B. *Boston Diagnostic Aphasia Examination*. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.

3. Delis D, Kramer J, Kaplan E, Ober B. *The California Verbal Learning Test, CVLT-II*. 2nd ed. San Antonio, TX: Psychological Corp; 2000.
4. Brown SG, Roy EA, Rohr LE, Snider BR, Bryden PJ. Preference and performance measures of handedness. *Brain Cogn*. 2004;55(2):283-285.
5. Tombaugh TN. *Test of Memory Malingering*. North Tonawanda, NY: Multi-Health Systems; 1996.
6. Reitan R. The validity of the Trail Making Test as an indicator of organic brain damage. *Percept Mot Skills*. 1958;8:271-276.
7. Wechsler D. *WAIS-IV Technical Manual*. New York, NY: Psychological Corp; 2008.
8. Chlebowski C. *Wechsler Memory Scale All Versions*. New York, NY: Springer; 2011.
9. Beck AT, Steer RA, Brown GK. *Beck Depression Inventory Manual*. 2nd ed. San Antonio, TX: Psychological Corp; 1996.
10. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol*. 1988;56(6):893-897.
11. Beck AT, Steer RA. *Beck Anxiety Inventory Manual*. San Antonio, TX: Psychological Corp; 1993.
12. Grace J, Malloy PF. *The Frontal Systems Behavior Scale (FrSBe)*. Odessa, FL: Psychological Assessment Resources; 2002.
13. Weathers FW, Huska JA, Keane TM. *PCL-C for DSM-IV*. Boston, MA: National Center for PTSD-Behavioral Science Division; 1991.
14. McCutchan PK, Freed MC, Low EC, Belsher BE, Engel CC. Rescaling the Post-Traumatic Stress Disorder Checklist for use in primary care. *Mil Med*. 2016;181(9):1002-1006.
15. Wrisley DM, Marchetti GF, Kuharsky DK, Whitney SL. Reliability, internal consistency, and validity of data obtained with the Functional Gait Assessment. *Phys Ther*. 2004;84(10):906-918.
16. Powell LE, Myers AM. The Activities-Specific Balance Confidence (ABC) Scale. *J Gerontol A Biol Sci Med Sci*. 1995;50A(1):M28-M34.
17. Bell DR, Guskiewicz KM, Clark MA, Padua DA. Systematic review of the Balance Error Scoring System. *Sports Health*. 2011;3(3):287-295.
18. Horn LB, Rice T, Stoskus JL, Lambert KH, Dannenbaum E, Scherer MR. Measurement characteristics and clinical utility of the Clinical Test of Sensory Interaction on Balance (CTSIB) and Modified CTSIB in individuals with vestibular dysfunction. *Arch Phys Med Rehabil*. 2015;96(9):1747-1748.

19. Shumway-Cook A, Horak FB. Assessing the influence of sensory interaction of balance: suggestion from the field. *Phys Ther*. 1986;66(10):1548-1550.
20. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. *Arch Otolaryngol Head Neck Surg*. 1990;116(4):424-427.
21. Alahmari KA, Marchetti GF, Sparto PJ, Furman JM, Whitney SL. Estimating postural control with the balance rehabilitation unit: measurement consistency, accuracy, validity, and comparison with dynamic posturography. *Arch Phys Med Rehabil*. 2014;95(1):65-73.
22. Nashner LM. Computerized dynamic posturography. In: Jacobson GP, Newman CW, Kartush JM, eds. *Handbook of Balance Function Testing*. St Louis, MO: Mosby Yearbook; 1993:280-304.
23. Barin K. Interpretation and usefulness of caloric testing. In: Jacobson GP, Shepard NT, eds. *Balance Function Assessment and Management*. San Diego, CA: Plural Publishing; 2008:229-249.
24. Shepard N, Telian S. *Practical Management of the Balance Disorder Patient*. San Diego, CA: Singular Publishing; 1996.
25. Scheiman M, Wick B. *Clinical Management of Binocular Vision: Heterophoric, Accommodative and Eye Movement Disorders*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014.
26. Gallaway M, Scheiman M, Mitchell GL. Vision therapy for post concussion vision disorders. *Optom Vis Sci*. 2017;94(1):68-73.
27. Rouse M, Borsting E, Mitchell GL, et al; Convergence Insufficiency Treatment Trial (CITT) Investigator Group. Validity of the Convergence Insufficiency Symptom Survey: a confirmatory study [published correction appears in *Optom Vis Sci*. 2009;86(6):786]. *Optom Vis Sci*. 2009;86(4):357-363.
28. Garzia RP, Richman JE, Nicholson SB, Gaines CS. A new visual-verbal saccade test: the Development Eye Movement test (DEM). *J Am Optom Assoc*. 1990;61(2):124-135.
29. Mucha A, Collins MW, Elbin RJ, et al. A brief Vestibular/Ocular Motor Screening (VOMS) assessment to evaluate concussions: preliminary findings. *Am J Sports Med*. 2014;42(10):2479-2486.
30. Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. *Exp Neurol*. 2013;246:35-43.
31. Alderfer BS, Arciniegas DB, Silver JM. Treatment of depression following traumatic brain injury. *J Head Trauma Rehabil*. 2005;20(6):544-562.
32. Bryant R. Post-traumatic stress disorder vs traumatic brain injury. *Dialogues Clin Neurosci*. 2011;13(3):251-262.
33. Jorge RE, Arciniegas DB. Mood disorders after TBI. *Psychiatr Clin North Am*. 2014;37(1):13-29.
34. Jones TF, Craig AS, Hoy D, et al. Mass psychogenic illness attributed to toxic exposure at a high school. *N Engl J Med*. 2000;342(2):96-100.
35. Weir E. Mass sociogenic illness. *CMAJ*. 2005;172(1):36.
36. Shenton ME, Hamoda HM, Schneiderman JS, et al. A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury. *Brain Imaging Behav*. 2012;6(2):137-192.
37. McInnes K, Friesen CL, MacKenzie DE, Westwood DA, Boe SG. Mild traumatic brain injury (mTBI) and chronic cognitive impairment: a scoping review. *PLoS One*. 2017;12(4):e0174847.
38. Bigler ED. Neuropsychology and clinical neuroscience of persistent post-concussive syndrome. *J Int Neuropsychol Soc*. 2006;14(1):1-22.



**From:** Moundalexis, Athena M  
**Sent:** 4 Apr 2018 17:23:49 +0000  
**To:** David Brody  
**Cc:** Tabak, Lawrence (NIH/OD) [E]; Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]; Munoz, Mark L; Rosenfarb, Charles H  
**Subject:** RE: Setting up a time to meet

Thanks.

**Official**  
**UNCLASSIFIED**

---

**From:** David Brody [mailto:david.brody@usuhs.edu]  
**Sent:** Wednesday, April 04, 2018 1:22 PM  
**To:** Moundalexis, Athena M  
**Cc:** Tabak, Lawrence (NIH/OD) [E]; Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]; Munoz, Mark L; Rosenfarb, Charles H  
**Subject:** Re: Setting up a time to meet

All

I'm happy to help to the best of my ability.

I have some awareness of this situation from a previous State Dept meeting at Usuhs earlier this year.

Best,

Db.

Sent from my iPhone

On Apr 4, 2018, at 12:31 PM, Moundalexis, Athena M <[MoundalexisAM@state.gov](mailto:MoundalexisAM@state.gov)> wrote:

Hi all,

While we are still working on the timing, attached please find some read-ahead materials. For location, would you like us to come to NIH?

Dr. Brody,

We would welcome your participation.

Thanks.

Athena

**Official**  
**UNCLASSIFIED**

**From:** Koroshetz, Walter (NIH/NINDS) [E]  
**Sent:** 4 Apr 2018 23:08:56 +0000  
**To:** Volkow, Nora (NIH/NIDA) [E]; Tabak, Lawrence (NIH/OD) [E]; Moundalexis, Athena M  
**Cc:** Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Carly Larkin; David Brody; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]; david.brody@usuhs.edu; Munoz, Mark L; Rosenfarb, Charles H; Schulke, Hilda (NIH/NIDA) [E]  
**Subject:** RE: Setting up a time to meet

I have my Board of Scientific Counselors reporting to me that morning at 8 in downtown Bethesda. Usually done by 10:30. So might be a little late.

Best,  
 Walter

Walter J. Koroshetz, M.D.  
 Director, National Institute of Neurological Disorders and Stroke

**From:** Volkow, Nora (NIH/NIDA) [E]  
**Sent:** Wednesday, April 04, 2018 7:04 PM  
**To:** Tabak, Lawrence (NIH/OD) [E] <Lawrence.Tabak@nih.gov>; Moundalexis, Athena M <MoundalexisAM@state.gov>  
**Cc:** Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Gilman, James (NIH/CC/OD) [E] <james.gilman@nih.gov>; Gordon, Joshua (NIH/NIMH) [E] <joshua.gordon@nih.gov>; Koroshetz, Walter (NIH/NINDS) [E] <koroshetzw@ninds.nih.gov>; Carly Larkin <carly.larkin.ctr@usuhs.edu>; David Brody <david.brody@usuhs.edu>; Johnson, Alfred (NIH/OD) [E] <JohnsoA1@mail.nih.gov>; Simon, Dina (NIH/OD) [C] <dina.simon@nih.gov>; david.brody@usuhs.edu; Munoz, Mark L <MunozML@state.gov>; Rosenfarb, Charles H <rosenfarbch@state.gov>; Schulke, Hilda (NIH/NIDA) [E] <hilda.schulke@nih.gov>  
**Subject:** Re: Setting up a time to meet

This time work for me nora

---

**From:** "Tabak, Lawrence (NIH/OD) [E]" <lawrence.tabak@nih.gov>  
**Date:** Wednesday, April 4, 2018 at 5:08 PM  
**To:** "Moundalexis, Athena M" <MoundalexisAM@state.gov>  
**Cc:** "Harrison, Brian (HHS/IOS)" <Brian.Harrison@hhs.gov>, "Gilman, James (NIH/CC/OD) [E]" <james.gilman@nih.gov>, Joshua Gordon <joshua.gordon@nih.gov>, Walter Koroshetz <koroshetzw@ninds.nih.gov>, Carly Larkin <carly.larkin.ctr@usuhs.edu>, David Brody <david.brody@usuhs.edu>, Nora Volkow <nvolkow@nida.nih.gov>, "Johnson, Alfred (NIH/OD) [E]" <johnsoa1@mail.nih.gov>, "Simon, Dina (NIH/OD) [C]" <dina.simon@nih.gov>, "david.brody@usuhs.edu" <david.brody@usuhs.edu>, "Munoz, Mark L" <MunozML@state.gov>, "Rosenfarb, Charles H" <rosenfarbch@state.gov>  
**Subject:** Re: Setting up a time to meet

Will check and get back to you by tomorrow.

Best wishes,

Larry

---

**From:** "Moundalexis, Athena M" <[MoundalexisAM@state.gov](mailto:MoundalexisAM@state.gov)>  
**Date:** Wednesday, April 4, 2018 at 5:06 PM  
**To:** "Tabak, Lawrence (NIH/OD) [E]" <[lawrence.tabak@nih.gov](mailto:lawrence.tabak@nih.gov)>  
**Cc:** "Harrison, Brian (HHS/IOS)" <[Brian.Harrison@hhs.gov](mailto:Brian.Harrison@hhs.gov)>, "Gilman, James (NIH/CC/OD) [E]" <[james.gilman@nih.gov](mailto:james.gilman@nih.gov)>, "Gordon, Joshua (NIH/NIMH) [E]" <[joshua.gordon@nih.gov](mailto:joshua.gordon@nih.gov)>, "Koroshetz, Walter (NIH/NINDS) [E]" <[koroshetzw@ninds.nih.gov](mailto:koroshetzw@ninds.nih.gov)>, Carly Larkin <[carly.larkin.ctr@usuhs.edu](mailto:carly.larkin.ctr@usuhs.edu)>, David Brody <[david.brody@usuhs.edu](mailto:david.brody@usuhs.edu)>, "Volkow, Nora (NIH/NIDA) [E]" <[nvolkow@nida.nih.gov](mailto:nvolkow@nida.nih.gov)>, "Johnson, Alfred (NIH/OD) [E]" <[johnsoa1@mail.nih.gov](mailto:johnsoa1@mail.nih.gov)>, "Simon, Dina (NIH/OD) [C]" <[dina.simon@nih.gov](mailto:dina.simon@nih.gov)>, "david.brody@usuhs.edu" <[david.brody@usuhs.edu](mailto:david.brody@usuhs.edu)>, "Munoz, Mark L" <[MunozML@state.gov](mailto:MunozML@state.gov)>, "Rosenfarb, Charles H" <[rosenfarbch@state.gov](mailto:rosenfarbch@state.gov)>  
**Subject:** RE: Setting up a time to meet

Hi,

Would April 17<sup>th</sup> at 10 am work for NIH? This is the earliest date that the content matter experts from

(b) (4) will be able to come down to NIH, and 10 am would give the

(b) (4)

(b) (4)

(b) (4)

Thanks all.

Athena Moundalexis

**Official**

**UNCLASSIFIED**

---

**From:** Moundalexis, Athena M  
**Sent:** Wednesday, April 04, 2018 12:30 PM  
**To:** 'Tabak, Lawrence (NIH/OD) [E]'  
**Cc:** Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]; 'david.brody@usuhs.edu'; Munoz, Mark L; Rosenfarb, Charles H (<[rosenfarbch@state.gov](mailto:rosenfarbch@state.gov)>)  
**Subject:** RE: Setting up a time to meet

Hi all,



While we are still working on the timing, attached please find some read-ahead materials.  
For location, would you like us to come to NIH?

Dr. Brody,  
We would welcome your participation.

Thanks.  
Athena

**Official**  
**UNCLASSIFIED**

---

**From:** Tabak, Lawrence (NIH/OD) [E] [mailto:lawrence.tabak@nih.gov]  
**Sent:** Wednesday, April 04, 2018 8:18 AM  
**To:** Moundalexis, Athena M  
**Cc:** Harrison, Brian (HHS/IOS); Gilman, James (NIH/CC/OD) [E]; Gordon, Joshua (NIH/NIMH) [E]; Koroshetz, Walter (NIH/NINDS) [E]; Volkow, Nora (NIH/NIDA) [E]; Johnson, Alfred (NIH/OD) [E]; Simon, Dina (NIH/OD) [C]  
**Subject:** Setting up a time to meet

Athena,

With this note I am electronically connecting you to Drs. Gilman ([https://www.cc.nih.gov/about/SeniorStaff/james\\_gilman.html](https://www.cc.nih.gov/about/SeniorStaff/james_gilman.html)), Gordon (<https://neuroscience.nih.gov/ninds/Faculty/Profile/joshua-gordon.aspx>), Koroshetz (<https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Directors-Corner>), and Volkow, (<https://www.drugabuse.gov/about-nida/directors-page>) each directors of relevant NIH institutes and centers. They also strongly recommend including Dr. David Brody at USUHS, who also conducts research at NIH (<https://www.usuhs.edu/national/faculty/david-brody-md-phd>). They are prepared to meet with you and Charles Ronsefarb as well as any other relevant content experts to be briefed on the situation discussed yesterday.

They have requested read-ahead materials detailing the medical findings so that they may best prepare.

Dina Simon in my office will coordinate with NIH staff if you could let me know dates/times when you team would be available to meet and where you want the meeting held.

Thanks, and best wishes,  
Larry

Lawrence A. Tabak, DDS, PhD  
Principal Deputy Director, NIH

--